[COMPANY_001] Research and Development  
INC424 
CINC424J12301 (I NCB [ZIP_CODE]-368) / [STUDY_ID_REMOVED]
Phase 3 r andomized, d ouble -blind, placebo -controlled, 
multi -center study to asses s the efficacy a nd safety of 
ruxolitinib in patients w ith COVID -19 associated cytokine 
storm (RUXCOVID) 
Document Type  Amended Protocol Version  
EUDRACT number:  2020 -001662 -11 
Version number:  01 (Clean ) 
Clinical Trial Phase:  III 
Release date:  20-May-2020
Property of [COMPANY_001]  / Incyte 
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of [COMPANY_001]  
Clinical Trial Protocol Template Version 3.0 dated 31- Jan-2020  
[COMPANY_001]  / Incyte  Confidential  Page 2 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
Table of contents 
Table of contents ................................................................................................................. [ADDRESS_465244] of abbreviations ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 10 
 12 
Protocol summary .............................................................................................................. 15 
1 Introduction ....................................................................................................................... 18 
1.1 Background ............................................................................................................ 18 
1.1.1  Ruxolitinib ............................................................................................. 19 
1.1.2  Additional evidence for CRS and JAK/STAT activation in severe 
respi[INVESTIGATOR_3765] ................................................................................. 19 
1.1.3  Back ground summary ........................................................................... 20 
1.2 Purpose .................................................................................................................. 21 
2 Objectives and endpoints ................................................................................................... 21 
2.1 Primary estimands  ................................................................................................. 23 
3 Study design ...................................................................................................................... 23 
4 Rationale  ............................................................................................................................ 25 
4.1 Rationale for study design ..................................................................................... 25 
4.2 Rationale for choice of background therapy .......................................................... 25 
4.3 Rationale for dose/regimen and duration of treatment  .......................................... 25 
4.4 Rationale for choice of control drugs (comparator/placebo) or combination drugs ...................................................................................................................... 26
 
4.5 Purpose and timing of interim analyses/design adaptations .................................. 26 
4.6 Risks and benefits .................................................................................................. 26 
5 Study Population ............................................................................................................... 27 
5.1 Inclusion criteria  .................................................................................................... 27 
5.2 Exclusion criteria  ................................................................................................... 28 
6 Treatment  ........................................................................................................................... 29 
6.1 Study treatment ...................................................................................................... 29 
6.1.1  Investigational and control drugs .......................................................... 29 
6.1.2  Supply of study treatment ..................................................................... 30 
6.1.3  Treatment arms/group  ........................................................................... 30 
6.1.4  Treatment duration  ................................................................................ 30 
6.2 Other treatments  ..................................................................................................... 30 
6.2.1  Concomitant therapy ............................................................................. 30 

[COMPANY_001]  / Incyte  Confidential  Page 3 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
6.2.2  Prohibited medication  ........................................................................... 31 
6.3 Participant numbering, treatment assignment, randomization  .............................. 31 
6.3.1  Participant numbering ........................................................................... 31 
6.3.2  Treatment assignment, randomization  .................................................. 32 
6.4 Treatment blinding  ................................................................................................. 32 
6.5 Dose escalation and dose modification  .................................................................. 32 
6.5.1  Dose modifications ................................................................................ 32 
6.6 Additional treatment guidance  ............................................................................... 33 
6.6.1  Treatment compliance  ........................................................................... 33 
6.6.2  Recommended treatment of adverse events  .......................................... 33 
6.6.3  Emergency breaking of assigned treatment code .................................. 34 
6.7 Preparation and dispensation ................................................................................. 35 
6.7.1  Handling of study treatment and additional treatment .......................... 35 
7 Informed consent procedures ............................................................................................ 35 
8 Visit schedule and assessments  ......................................................................................... 36 
8.1 Screening  ............................................................................................................... 42 
8.1.1  Information to be collected on screening failures ................................. 42 
8.2 Participant demographics/other baseline characteristics  ....................................... 42 
8.3 Efficacy  .................................................................................................................. 42 
8.3.1  Clinical status (9 -point ordinal scale) ................................................... 42 
8.3.2  Vital signs and oxygen saturation ......................................................... 43 
8.3.3  National Early Warning Score 2 (NEWS2)  .......................................... 43 
8.3.4  In-hospi[INVESTIGATOR_95209] ............................................................................. 43 
8.3.5  Ventilatory status  .................................................................................. 44 
8.3.6  Appropriateness of efficacy assessments  .............................................. 44 
8.4 Safety  ..................................................................................................................... 44 
8.4.1  Laboratory evaluations  .......................................................................... 44 
8.4.2  Physical Exam  ....................................................................................... 45 
8.4.3  Height, weight, BMI ............................................................................. 45 
8.4.4  Electrocardiogram (ECG)  ..................................................................... 45 
8.4.5  Pregnancy and assessments of fertility  ................................................. 45 
8.4.6  Appropriateness of safety measurements  .............................................. 46 
  46 
  46 
  46 
9 Study discontinuation and treatment ................................................................................. 47 

[COMPANY_001]  / Incyte  Confidential  Page 4 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
9.[ADDRESS_465245] to follow-up ................................................................................... 48 
9.1.5  Early study termination by [CONTACT_456] ................................................. 48 
9.2 Study completion ................................................................................................... 49 
10 Safety monitoring and reporting ........................................................................................ 49 
10.1  Definition of adverse events and reporting requirements ...................................... 49 
10.1.1  Adverse events  ...................................................................................... 49 
10.1.2  Serious adverse events  .......................................................................... 51 
10.1.3  SAE reporting........................................................................................ 52 
10.1.4  Pregnancy reporting .............................................................................. 52 
10.1.5  Reporting of study treatment errors including misuse/abuse ................ 52 
10.2  Additional Safety Monitoring ................................................................................ 53 
10.2.1  Liver safety monitoring ......................................................................... 53 
10.2.2  Data Monitoring Committee  ................................................................. 54 
11 Data Collection and Database management  ...................................................................... 54 
11.1  Data collection  ....................................................................................................... 54 
11.2  Database management and quality control  ............................................................ 55 
11.3  Site monitoring  ...................................................................................................... 55 
12 Data analysis and statistical methods  ................................................................................ 56 
12.1  Analysis sets .......................................................................................................... 56 
12.2  Participant demographics and other baseline characteristics  ................................. 56 
12.3  Treatments  ............................................................................................................. 57 
12.4  Analysis of the primary endpoint(s)/estimand(s) .................................................. 57 
12.4.1  Definition of primary endpoint(s)/estimand(s) ..................................... 57 
12.4.2  Statistical model, hypothesis, and method of analysis .......................... 57 
12.4.3  Handling of remaining intercurrent events of primary estimand  .......... 58 
12.4.4  Handling of missing values not related to intercurrent event ............... 58 
12.4.5  Sensitivity analyses for primary endpoint/estimand ............................. 58 
12.4.6  Supplementary analysis ......................................................................... 58 
12.4.7  Supportive analyses ............................................................................... 58 
12.5  Analysis of secondary endpoints/estimands .......................................................... 58 
12.5.1  Efficacy and/or Pharmacodynamic endpoint(s) .................................... 58 
12.5.2  Safety endpoints .................................................................................... 60 
[COMPANY_001]  / Incyte  Confidential  Page 5 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
  60 
  61 
  61 
12.7  Interim analyses  ..................................................................................................... 61 
12.8  Sample size calculation  .......................................................................................... 61 
12.8.1  Primary endpoint(s) ............................................................................... 61 
13 Ethical considerations and administrative procedures ...................................................... 62 
13.1  Regulatory and ethical compliance ........................................................................ 62 
13.2  Responsibilities of the investigator and IRB/IEC .................................................. 62 
13.3  Publication of study protocol and results............................................................... 62 
13.4  Quality Control and Quality Assurance ................................................................. 63 
14 Protocol adherence  ............................................................................................................ 63 
14.1  Protocol amendments ............................................................................................. 63 
15 References  ......................................................................................................................... 64 
16 Appendices ........................................................................................................................ 67 
16.1  Appendix 1: Liver event and laboratory trigger definitions & follow-up 
requirements  .......................................................................................................... 67 
16.2  Appendix 2: Clinical status 9 -point scale .............................................................. 70 
16.3  Appendix 3: National Early Warning Score 2 (NEWS2) ...................................... 71 
16.4  Appendix 4: List of CYP3A4 inhibitors and inducers........................................... [ADDRESS_465246] of tables 
Table 2 -1 Objectives and related endpoints  .......................................................... 21 
Table 6 -1 Investigational and control drug ............................................................ 30 
Table 8-1  Assessment Schedule  ............................................................................ 38 
Table 8 -2 Clinical status 9 -category ordinal scale  ................................................. 42 
Table 10 -1 Guidance for capturing the study treatment errors including misuse/abuse ......................................................................................... 53
 
Table 12 -1 Sensitivity of sample size assumptions to different failure  rates for 
level of significance alpha = 0.05 ......................................................... 61 
Table 16 -1 Liver event and laboratory trigger definitions ...................................... 67 
Table 16 -2 Follow up requirements for liver laboratory triggers with liver symptoms .............................................................................................. 68
 
Table 16 -3 Follow up requirements for liver laboratory triggers ............................ 69 
Table 16 -4 CYP3A4 inhibitors and inducers .......................................................... 73 
 

[COMPANY_001]  / Incyte  Confidential  Page 6 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
List of figures 
Figure 3-1  Study design .......................................................................................... 24 
 
[COMPANY_001]  / Incyte  Confidential  Page 7 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
List of abbreviations 
AE Adverse Event  
ALP Alkaline Phosphatase  
ALT Alanine Aminotransferase  
ANCOVA  Analysis of covariance  
ARDS  Acute respi[INVESTIGATOR_371876]  
b.i.d.  bis in die/twice a day  
BMI Body Mass Index  
BUN  Blood Urea Nitrogen  
CART  Chimeric antigen receptor T cells  
CK Creatine Kinase  
CMO&PS  Chief Medical Office and Patient Safety  
CoV Corona virus  
COVID -[ADDRESS_465247] X -Ray 
CYP3A4  cytochrome P450 3A4  
dL deciliter  
DMC  Data Monitoring Committee  
  
ECG  Electrocardiogram  
ECMO  Extracorporeal membrane oxygenation  
eCRF  Electronic Case Report/Record Form  
EDC  Electronic Data Capture  
eSource  Electronic Source  
FDA Food and Drug Administration  
FiO [ADDRESS_465248] Domain E3 Ubiquitin Protein Ligase 2  
HHS  Health and Human Services  

[COMPANY_001]  / Incyte  Confidential  Page 8 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
HLH haemophagocytic lymphohistiocytosis  
HU hydroxyurea  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use  
ICU Intensive Care Unit  
IEC Independent Ethics Committee  
IN Investigator Notification  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
JAK Janus kinase  
LPS Lipopolysaccharides  
MedDRA  Medical dictionary for regulatory activities  
MF Myelofibrosis  
mg milligram(s)  
mL milliliter(s)  
MOF  Multi organ failure  
NEWS2  National Early Warning Score 2  
PaO 2 Partial pressure of arterial oxygen  
PCR  Polymerase chain reaction  
PD Pharmacodynamic(s)  
PET-MF post-essential thrombocythemia myelofibrosis  
PI[INVESTIGATOR_371877](s)  
PMF  Primary myelofibrosis  
PML Progressive multifocal leuko -encephalopathy  
POM  Proportional odds model  
PPV-MF post-polycythemia vera myelofibrosis  
PREP Act  Public Readiness and Emergency Preparedness Act  
PT prothrombin time  
QMS  Quality Management System  
RBC  red blood cell(s)  
RDO  Retrieved Drop Out  
RNA  Ribonucleic acid  
RRT Renal Replacement Therapy  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SARS -CoV severe acute respi[INVESTIGATOR_7686] -corona virus  
SGOT  Serum Glutamic Oxaloacetic Transaminase  
SGPT  Serum Glutamic Pyruvic Transaminase  
[COMPANY_001]  / Incyte  Confidential  Page 9 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
SoC Standard -of-Care  
STAT  signal transducers and activators of transcription  
TD Study Treatment Discontinuation  
ULN upper limit of normal  
WBC  white blood cell(s)  
WHO  World Health Organization  
WoC  Withdrawal of Consent  
[COMPANY_001]  / Incyte  Confidential  Page 10 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
Glossary of terms 
Additional 
treatment  Medicinal products that may be used during the clinical trial as described in the protocol, but not as an investigational medicinal product (e.g. any 
background t herapy)  
Assessment  A procedure used to generate data required by [CONTACT_6551]  A biological specimen including, for example, blood (plasma, serum), saliva, 
tissue, urine, stool, etc. taken from a study participant  
Cohort  A specific group of participants fulfilling certain criteria and generally treated at 
the same time  
Control dru g A study drug (active or placebo) used as a comparator to reduce assessment bias, preserve blinding of investigational drug, assess internal study validity, 
and/or evaluate comparative effects of the investigational drug  
Dosage  Dose of the study treatment given to the participant in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)  
Electronic Data 
Capture (EDC)  Electronic data capture (EDC) is the electronic acquisition of clinical study data using data collection systems, such as Web- based applications, 
interactive voice response systems and clinical laboratory interfaces. EDC 
includes the use of Electronic Case Report Forms (eCRFs) which are used to 
capture data transcribed from paper source forms used at the point of care  
End of the clinical 
trial The end of the clinical trial is defined as the last visit of the last participant or 
at a later point in time as defined by [CONTACT_30761]/time of participant entry into the study at which informed consent must 
be obtained  
Estimand  A precise description of the treatment effect reflecting the clinical question 
posed by [CONTACT_6553]. It summarizes at a population- level what the 
outcomes would be in the same patients under different treatment conditions 
being compared. Attributes of an estimand include the population, variable (or 
endpoint) and treatment of interest, as well as the specification of how the remaining intercurrent events are addressed and a population- level summary 
for the variable.  
Intensive care unit 
(ICU) An Intensive Care Unit is defined as any setting in which patients are receiving therapy typi[INVESTIGATOR_371878] (e.g., vasopressors, 
mechanical ventilation, etc .) or monitoring that is typi[INVESTIGATOR_371879] ( e.g.,invasive arterial or central venous monitoring).  
Intercurrent events  Events occurring after treatment initiation that affect either the interpretation or 
the existence of the measurements associated with the clinical question of 
interest.  
Investigational  
drug/ treatment  The drug whose properties are being tested in the study  
Medication 
number  A unique identifier on the label of medication kits  
Mis-randomized 
participants  Mis-randomized participants are those who were not qualified for 
randomization and who did not take study treatment, but have been 
inadvertently randomized into the study  
Other treatment  Treatment that may be needed/allowed during the conduct of the study ( i.e. 
concomitant or rescue therapy)  
Participant  A trial participant (can be a healthy volunteer or a patient)  
[COMPANY_001]  / Incyte  Confidential  Page 11 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
Participant number  A unique number assigned to each participant upon signing the informed 
consent. This number is the definitive, unique identifier for the participant and should be used to identify the participant throughout the study for all data 
collected, sample labels, etc.  
Period  The subdivisions of the trial design (e.g. Screeni ng, Treatment, Follow -up) are 
described in the Protocol. Periods define the study phases and will be used in 
clinical trial database setup and eventually in analysis  
Personal data  Participant information collected by [CONTACT_157058]. This data includes 
participant identifier information, study information and biological samples.  
Premature 
participant 
withdrawal  Point/time when the participant exits from the study prior to the planned 
completion of all study drug administration and/or assessments; at this time all study drug administration is discontinued and no further assessments are 
planned  
Randomization 
number  A unique identifier assigned to each randomized participant  
Screen Failure  A participant who did not  meet one or more criteria that were required for 
participation in the study  
Source Data/Document  Source data refers to the initial record, document, or primary location from where data comes. The data source can be a database, a dataset, a 
spreadsheet or  even hard -coded data, such as paper or eSource  
Start of the clinical 
trial The start of the clinical trial is defined as the signature [CONTACT_201698] [CONTACT_371922]; includes investigational 
drug(s), control(s) or background therapy  
Study treatment 
discontinuation  When the participant permanently stops taking any of the study  drug(s) prior 
to the defined study treatment completion date (if any) for any reason; may or 
may not also be the point/time of study discontinuation  
Treatment 
arm/group  A treatment arm/group defines the dose and regimen or the combination, and 
may consist of [ADDRESS_465249], which might or might not be the same 
as the study treatment.  
Variable (or 
endpoint)  The variable (or endpoint) to be obtained for each participant that is required to address the clinical question.  The specification of the variable might include 
whether the participant experiences an interc urrent event.  
Withdrawal of 
study consent (WoC)  Withdrawal of consent from the study occurs only when a participant does not want to participate in the study any longer and does not allow any further collection of personal data  
[COMPANY_001]  / Incyte  Confidential  Page 12 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 

[COMPANY_001]  / Incyte  Confidential  Page 13 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  

[COMPANY_001]  / Incyte  Confidential  Page 14 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  

[COMPANY_001]  / Incyte  Confidential  Page 15 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
Protocol summary  
Protocol number  CINC424J12301  
Full Title  Phase 3 randomized , double- blind, placebo- controlled, multi -
center study to assess the efficacy and safety of ruxolitinib in 
patients with COVID -19 associated cytokine storm  
Brief title  RUXCOVID  
Sponsor and 
Clinical Phase  [COMPANY_001]  
III 
Investigation type  Drug  
Study type  Interventional  
Purpose and rationale  There are no approved treatments for COVID -19 pneumonia. 
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID -19 
pneumonia.  
Primary Objective(s)  To evaluate the efficacy (as measured by a composite endpoint 
of proportion of patients who die, develop respi[INVESTIGATOR_1399] 
[require mechanical ventilation] , or require intensive care unit 
[ICU] care) of ruxolitinib + standard- of-care (SoC) therapy 
compared with placebo + SoC therapy, for the treatment of 
COVID -19 by [CONTACT_2006] 29 . 
Secondary Objectives  To evaluate the efficacy (as measured by [CONTACT_371923] a 9-point ordinal scale) of ruxolitinib + SoC therapy compared with 
placebo + SoC  therapy, for the treatment of COVID -19. 
To evaluate the efficacy of ruxolitinib + standard- of-care (SoC) 
therapy compared with placebo + SoC therapy, on in- hospi[INVESTIGATOR_371880] -19. 
To evaluate the efficacy of ruxolitinib + SoC therapy,  compared 
with placebo + SoC therapy, in change in the National Early Warning Score (NEWS2) score in patients with COVID -19. 
To evaluate the efficacy of ruxolitinib + SoC therapy, compared 
with placebo + SoC therapy, in change in SpO
2/FiO 2 ratio in 
patient s with COVID -19. 
To evaluate the efficacy of ruxolitinib + SoC therapy, compared 
with placebo + SoC therapy, in proportion of patients with no oxygen therapy (defined as oxygen saturation ≥ 94% on room air) in patients with COVID -19. 
To evaluate the safety of  ruxolitinib + standard- of-care (SoC) 
therapy compared with placebo + SoC therapy, in the treatment 
of patients with COVID -19. 
Study design  This is a randomized, double- blind, placebo- controlled, 29- day, 
multi -center study to assess the efficacy and safety of ruxolitinib 
+ SoC therapy, compared with placebo + SoC therapy, in 
patients aged ≥12 years with COVID -19 pneumonia . 
Study population  Approximately 402 m ales and females ages 12 and older with 
COVID -19 pneumonia . 
[COMPANY_001]  / Incyte  Confidential  Page 16 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
Key Inclusion criteria  • Patient or guardian/health proxy must provide informed 
consent (and assent if applicable) before any study assessment 
is performed.  
• Male and female patients aged ≥ 12 years (or ≥ the lower 
age limit allowed by [CONTACT_371924]/or Ethics Committee/Institutional Review Board approvals).  
• Patients with coronavirus (SARS- CoV-2) infection confirmed 
by [CONTACT_940] (PCR) test or another rapid test from the respi[INVESTIGATOR_371881]. 
• Patients currently hospi[INVESTIGATOR_371882].  
• Patients, who meet at least one of the below criteria:  
• Pulmonary infiltrates (chest X ray or chest CT scan);  
• Respi[INVESTIGATOR_249109] ≥ 30/min;  
• Requiring supplemental oxygen;  
• Oxygen saturation ≤ 94% on room air;  
• Arterial oxygen partial pressure (PaO2)/ fraction of 
inspi[INVESTIGATOR_1401] (FiO 2) < 300mmHg (1mmHg=0.133kPa) 
(corrective formulation should be used for higher altitude 
regions (over 1000m).  
Key Exclusion criteria  • History of hypersensitivity to any drugs or metabolites of 
similar chemical classes as ruxolitinib.  
• Presence of severely impaired renal function defined by 
[CONTACT_89408] > 2 mg/dL (>176.8 μmol/L), or have estimated creatinine clearance < 30 ml/min measured or calculated by [CONTACT_371925].  
• Suspected uncontrolled bacterial, fungal, viral, or other 
infection (besides COVID -19). 
• Currently intubat ed or intubated between screening and 
randomization.  
• In intensive care unit (ICU) at time of randomization.  
• Intubated or i n ICU for COVID -19 disease prior to screening.  
• Patients who are on anti -rejection, immunosuppressant or 
immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra).  
• Unable to ingest tablets at randomization.  
• Pregnant or nursing (lactating) women.  
Study treatment Ruxolitinib [ADDRESS_465250]  
 Ruxolitinib 5 mg tablets  
[COMPANY_001]  / Incyte  Confidential  Page 17 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
Efficacy assessments  Clinical status using a 9-category ordinal scale  
Vital signs and oxygen saturation  
National Early Warning Score (NEWS2)  
In-hospi[INVESTIGATOR_371883], physical examinations, monitoring of 
laboratory markers in blood, ECGs.  
   
 
Data analysis  The primary endpoint will be analyzed using the randomized set. 
The odds of clinical failure will be analyzed by a logistic 
regression model with treatment  group, country, age, and 
gender as covariates. The estimated odds ratio, p- values, and 
95% confiden ce intervals will be presented.  
Key words  
 COVID -19 pneumonia, SARS -COV -2, ruxolitinib  

[COMPANY_001]  / Incyte  Confidential  Page 18 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
1 Introduction 
1.1 Background 
In December 2019, the Wuhan Municipal Health Committee identified an outbreak of viral 
pneumonia cases of unknown cause. This outbreak of viral pneumonia was reported to the World Health Organization (WHO) Country Office in China on December 31, 2019. Subs equently, Coronavirus (CoV) RNA was identified in some of  patients with viral pneumonia.  
Coronaviruses are positive -stranded RNA viruses with a crown -like appearance under an 
electron microscope due to the presence of spi[INVESTIGATOR_371884]. T hey are a 
large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East respi[INVESTIGATOR_7686] (MERS -CoV) and severe acute respi[INVESTIGATOR_7686] 
(SARS -CoV).  
The novel coronavirus detected in late 2019 has been designated SARS -CoV -2, and the disease 
caused by [CONTACT_371926] -19, an acronym for "coronavirus disease 
2019". This new coronavirus strain was not  previously identified in humans and was newly 
named on [ADDRESS_465251] people with COVID -19 develop mild or uncomplicated illness, approximately 14% 
develop severe disease requiring hospi[INVESTIGATOR_371885] 5% require admiss ion 
to an intensive care unit ( China CDC Weekly 2020). In severe cases, COVID -19 can be 
complica ted by [CONTACT_371927][INVESTIGATOR_320584] (ARDS), sepsis and septic shock, and/or 
multiorgan failure  (MOF), including acute kidney injury and cardiac injury ( Yang et al 2020).  
Of note, many patients with severe respi[INVESTIGATOR_371886] -[ADDRESS_465252] features 
consistent with the cytokine release syndrome (CRS), also referred to as cytokine storm, and 
increased activation of the JAK/STAT pathway ( Wang et al 2020; Hermans et al 2020). 
According to the WHO interim guidance of 13- Mar-2020 on the clinical management of severe 
acute respi[INVESTIGATOR_4416] (SARI) when COVID -19 disease is suspected, “older age and co -
morbid disease have been  reported as risk factors for death, and recent multivariable analysis 
confirmed older age, higher Sequential Organ Failure Assessment (SOFA) score and d- dimer > 
1 µg/L on admission were associated with higher mortality.” The same study quoted by [CONTACT_46318] a lso noted that the median duration of viral RNA detection was 20.0 days (IQR 17.0–
24.0) in survivors, but SARS -CoV- [ADDRESS_465253] observed duration of viral shedding in survivors was 37 days ( Huang et al 2020; Zhou 
et al 2020).  
There is sparse data on clinical presentation of COVID -19 in specific populations, such as 
children and pregnant women. In children with COVID -19, the s ymptoms are usually less 
severe than in adults and present mainly with cough and fever, and co- infection has been 
[COMPANY_001]  / Incyte  Confidential  Page 19 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
observed ( Cai et al 2020 ; Xia et al 2020 ). Relatively few cases have been reported of infants 
confirmed with COVID-19 and they experienced mild illness ( Wei et al 2020 ). 
1.1.1  Ruxolitinib  
Ruxolitinib (INCB018424 phosphate, INC424, ruxolitinib phosphate) is a well -established , 
potent and selective inhibitor of Janus kinase (JAK)[ADDRESS_465254] tyrosine kinase (TYK)2 and JAK3, respectively. Ruxolitinib interferes with the si gnaling of a number of cytokines and growth factors that are important for hematopoiesis 
and immune function as noted in the Ruxolitinib Investigator Brochure. 
JAK signaling involves recruitment of signal transducers and activators of transcription (STATs)  
to cytokine receptors, activation, and subsequent localization of STATs to the nucleus leading  
to modulation of gene expression. Dysregulation of the JAK/STAT pathway has been 
associated with several types of cancers and increased proliferation as well as  survival of  
malignant cells. In particular, this pathway may be dysregulated in majority of patients with  
Philadelphia chromosome -negative myeloproliferative neoplasms (MPNs), including 
myelofibrosis (MF) and polycythemia vera (PV), demonstrating that JAK  inhibition is 
efficacious in these diseases.  
Ruxolitinib (JAKAVI
®) is currently approved in the European Union (EU) for the treatment of 
disease- related splenomegaly or symptoms in adult patients with primary myelofibrosis (PMF)  
(also known as chronic idiopathic MF), post -polycythemia vera myelofibrosis (PPV -MF) or  
post- essential thrombocythemia myelofibrosis (PET -MF) and for the treatment of adult patients  
with PV who are resistant to or intolerant of hydroxyurea (HU). 
In the [LOCATION_002] (US),  ruxolitinib (JAKAFI®) is approved for the treatme nt of intermediate 
or high- risk MF, including PMF, PPV -MF and PET -MF in adults  and for treatment of adult 
patients with PV who have  had an inadequate response to or are intolerant of HU and for patients 
[ADDRESS_465255] disease (GvHD) . 
Ruxolitinib is currently under further development for the  treatment of MF, PV, essential 
thrombocytopenia (ET), and other hematologic malignanc ies. 
1.1.2  Additional evidence for CRS and JAK/STAT activation in severe 
respi[INVESTIGATOR_371887]/inhibition of the JAK/STAT pathway could have a beneficial effect on the CRS and the course of severe 
respi[INVESTIGATOR_159078]/ARDS in patients with COVID -19. 
[IP_ADDRESS]  Laboratory evidence  
Hermans et al (2020)  studied human mast cell lines and demonstrated that ruxolitinib can inhibit 
mast cell activity, possibly through prevention of STAT5 activation. They postulated that the JAK- STAT pathway is an interesting target for therapy to release symptom burden in 
mastocytosis and many other mast cell mediator related diseases such as the CRS . 
Hoffman et al (2016)  demonstrated that viral and bacterial co -infection in a macrophage model 
modulates the JAK -STAT signaling pathway and leads to exacerbated IP -10 expression, which 
[COMPANY_001]  / Incyte  Confidential  Page 20 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
could play a major role in the pathogenesis of pneumonia, suggesting that targeting this pat hway 
could have a beneficial effect.  
[IP_ADDRESS]  Animal models  
Zhao et al (2016)  looked at LPS -induced lung injury in m ice, which models some of the ARDS 
(e.g. cytokine increases and cell influx) manifestations, as well as an increase in STAT3 
expression. STAT3 is downstream of JAK and the authors show that STAT3 inhibition with a 
tool compound partly inhibits cytokine and cell increases after LPS challenge. A c aveat is that 
a positive control (e .g. dexamethasone) is absent from the in vivo studies. Using conditional 
knockouts of SOCS3 (an antinflammatory protein which negatively regulates JAK activity) they provide further evidence that the effects are STAT3 pat hway dependent. They also show 
increased STAT3 expression in PBMC from ARDS patients could be blocked with the same 
tool compound. 
Coon et al (2015)  identified a new ubiquitinylating ligase HECTD2 which degrades PIA S-1, an 
antinflammatory  protein which negatively regulates the JAK -STAT pathway. They show 
degradation of PI[INVESTIGATOR_371888]2 induces lung inflammation (cytokine increases and cell 
counts) in a mouse pneumonia challenge model. HECTD2 inhibitor reduces lung infl ammation 
in the same model (no positive control). They also identify a polymorphism (loss of function) in the HECTD2 gene which appears to be protective against ARDS. 
Kenderian et al (2017)  described for the first t ime a clinically relevant animal model of human 
CRS and demonstrated that the JAK/STAT inhibitor ruxolitinib can prevent the development 
of severe CRS without impairing the anti -tumor effect of CART cells. These findings provide 
a useful platform for the future study of CRS prevention and treatment modalities. These experiments indicate that ruxolitinib could also be combined with CART cell therapy for the prevention of CRS in patients identified to be at high risk for the development of CRS. 
Calbet et al (2019)  studied a novel pan- JAK inhibitor and showed that it reduced allergen -
induced airway inflammation, late asthmatic response, and PSTAT activation in rats. Maschalidi et al (2016)  described  in a mouse model of haemophagocytic lymphohistiocytosis 
(HLH)  (model of CRS), administration of ruxolitinib suppressed the harmful consequences of 
macrophage activation with improvement in vital signs and he matologic parameters.  
[IP_ADDRESS]  Clinical  evidence  
There  is clinical evidence of efficacy with ruxolitinib in another recognized disease with CRS: 
secondary HLH. Two pi[INVESTIGATOR_371889]; alleviating need for more toxic therapi[INVESTIGATOR_014].  
(Ahmed 2019; Goldsmith 2019).  
1.1.[ADDRESS_465256] clinical features consistent with CRS and 
increased activation of the JAK/STAT pathway ( Wang et al 2020; Hermans et al 2020). 
Moreover, r ecent literature specifically suggests consideration of molecules for treatment of 
[COMPANY_001]  / Incyte  Confidential  Page 21 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
COVID- 19 that block inflammatory pathways, including inhibition of the JAK/STAT pathway 
where a number of cytokines converge ( Zumla et al 2020, Mehta et al 2020 ). 
In summary, the above -mentioned data provide scientific justification for the study of a 
JAK/STAT inhibitor, such as ruxolitinib, in a controlled clinical trial setting.  
1.2 Purpose 
There are no approved treatments for COVID -19 pneumonia. The purpose of this study is to 
evaluate the ef ficacy and safety of ruxolitinib in the treatment of patients with COVID -19 
pneumonia.  
2 Objectives and endpoints  
Table 2-1 Objectives and related endpoints  
 Objectives  Endpoints  
Primary 
Objective  To evaluate the efficacy (as 
measured by a composite endpoint 
of proportion of patients  who die, 
develop respi[INVESTIGATOR_1399] [ require 
mechanical ventilation] , or require 
intensive care unit [ ICU] care) of 
ruxolitinib  + standard- of-care (SoC) 
therapy compared with placebo + 
SoC therapy, for the treatment of 
COVID -19 by [CONTACT_2006] 29 . Composite endpoint defined as:  
• Death OR  
• Respi[INVESTIGATOR_1399] (require 
mechanical ventilation) OR  
• Intensive care unit (ICU) care by 
[CONTACT_2006] 29.  
Secondary 
Objectives  To evaluate the efficacy (as measured by [CONTACT_371923] a 9-point ordinal scale) of ruxolitinib + 
SoC therapy compared with placebo 
+ SoC therapy, for the treatment of COVID -19 (WHO 18-Feb-2020).  Clinical status assessed using a 9-point 
ordinal scale ( Appendix 2) at Day 15 and 
Day 29. 
• Percentage of patients with a better 
category (lower number) in clinical status 
at Day 15 and at Day 29.  
• Percentage of patients with at least 
two-point improvement in clinical status 
at Day 15 and at Day 29.  
• Percentage of patients with at least 
one-point improvement in clinical status 
at Day 15 and at Day 29.  
• Percentage of patients with at least 
one-point deterioration in clinical status 
at Day 15 and at Day 29.  
• Time to improvement from baseline 
category to one less severe category of the ordinal sc ale. 
• Mean change in the 9- point ordinal 
scale from baseline to Days 15 and 29.  
[COMPANY_001]  / Incyte  Confidential  Page 24 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
The study will include: 
• Screening period  of 0-2 days 
• Study period of 29 days (treatment of 14 days ; an additional 14 days of study drug may 
be given, if in the opi[INVESTIGATOR_871], the patient’s clinical signs and symptoms are 
not improved or worsen and the potential benefit outweighs the potential risk) – see below. 
Figure 3-1 Study design  
 
Note: Should a patient become intubated during the Study Period, study medication may be given via 
a nasogastric tube (see Section 6.1.1 for direc tions).  
Eligible patients will be randomized on the same day as screening or up to two  days after 
completing the screening procedures . At Day 1  (randomization visit), patients will be assigned 
in a 2:1 ratio to receive oral ruxolitinib 5 mg twice daily or oral matching -image placebo for a 
total of 14 days ( Section 6.1). An additional 14 days of study drug may be given, if in the 
opi[INVESTIGATOR_871], the patient’s clinical signs and symptoms are not improved or 
worsen and the potential benefit outweighs the potential risk. 
Study treatment will be given in combination with SoC therapy according to the investiga tor’s 
clinical judgement . Should a patient become intubated during the Study Period, study 
medication may be given via a nasogastric tube (see Section 6.1.1 for directions ). 
Randomization will be stratified b y region ( North  America, Europe ). 
Patients who do not meet the criteria for participation in this study (screen failure s) may not be 
re-screened.  
Assessments during the Study Period will occur per the schedule of study assessments (See 
Section 8 ) for specific assessments and timing for these assessments). The primary endpoint for 
the study will be  the proportion of patients  who die, develop respi[INVESTIGATOR_371890] (require 
mechanical ventilation), or require ICU care by [CONTACT_2006] 29. Should a patient be discharged from the hospi[INVESTIGATOR_371891] 29 -day study period, daily assessment of clinical status will be made via 
a telephone call to the patient each day (between 7 AM and 12 PM), with the exception of Day 15 and Day 29, during which discharged patients will return for an in- clinic visit.  For Day 15 
and Day 29, i f an in -clinic visit is not possible, the visit may be performed in an appropriate 
setting, including at home, with appropriate study personnel. 

[COMPANY_001]  / Incyte  Confidential  Page 25 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
This study will include an internal data monitoring committee (DMC) which will function 
independently of all other individuals associated with the conduct of this clinical trial, including 
the site investigators partic ipating in the study. 
4 Rationale  
4.1 Rationale for study design  
This randomized, double -blind, parallel -group, placebo- controlled, design supports the rigorous 
assessment of efficacy as well as safety of ruxolitinib as add -on to SoC therapy for pa tients with 
COVID-19 pneumonia. 
Screening Per iod 
The screening period all ows for assessment of patient entry criteria to ensure suitable patients 
are entered into the study. Screening and randomization may occur on the same day. Study Period  
During this period, oral ruxolitinib 5 mg twice daily or oral matching -image placebo twice daily 
(randomized 2:1) will be administered 14 days. An additional 14 days of study drug may be 
given, if in the opi[INVESTIGATOR_871], the patient’s clinical signs and symptoms are not 
improved or worsen and the potential benefit outweighs the potential risk . The endpoints 
included in this study measure clinical status, clinical and in -hospi[INVESTIGATOR_95209], and laboratory 
values during the 29-day Study Period. These measurements are consistent with endpoints and measurement times for other studies o f therapi [INVESTIGATOR_371892] -19 ( WHO 18-Feb-
2020; Cao et al 2020).  
4.2 Rationale for choice of background therapy 
Although there are no approved treatments for COVID -19, SoC therapy for patients with 
COVID- 19 pneumonia generally includes supportive care and anti -viral treatments. Thus, 
placebo + SoC  therapy is appropriate as a control in this study. 
4.3 Rationale for dose/regimen and duration of treatment 
The ruxolitinib dose regimen chosen in this study is the lowest efficacious dose based on 
pharmacokinetic data. Ruxolitinib [ADDRESS_465257] ( Jagasia et al 2020 ). Ruxolitinib 5 mg twice daily is also the starting dose 
recommended for patients with myleofibrosis when platelets are 50 x 10
9/ L – <100 x 109/L. 
Cao et al (2020)  reported the median hospi[INVESTIGATOR_95237] -19 was 12 days with a n 
interquartile range of 1 to 14 days . Therefore, a duration of treatment for 14 days seems 
reasonable and has been selected for this study. An additional 14 days of study drug may be given, if in the opi[INVESTIGATOR_871], the patient’s clinical signs and symptoms are not improved or worsen and the potential benefit outweighs the potential risk. 
[COMPANY_001]  / Incyte  Confidential  Page 26 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
4.4 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs 
The study will evaluate the efficacy and safety of oral ruxolitinib  + SoC therapy , compared with 
matching -image  placebo + SoC therapy . Despi[INVESTIGATOR_371893] -19, 
SoC for patients with severe COVID -19 respi[INVESTIGATOR_371894] -viral agents. Therefore, S oC + placebo treatment is appropriate 
as a control i n this study. 
4.5 Purpose and timing of interim analyses/design adaptations 
No interim analysis is planned. An internal Data M onitoring Committee at [COMPANY_001] will be 
established to conduct periodic unblinded safety reviews. 
4.6 Risks and benefits 
There is preclini cal evidence from both laboratory and animal models that blockade/inhibition 
of the JAK/STAT pathway could have a beneficial effect on the CRS and the course of severe 
respi[INVESTIGATOR_3765]/ARDS in patients with COVID -19. Additionally, there is some clinical 
evidence of efficacy with ruxolitinib in pi[INVESTIGATOR_371895] r recognized disease with CRS: 
secondary HLH ( See Section 1.1.1).  However, ruxolitinib has not previously been studied in 
patients with COVID -[ADDRESS_465258] frequent treatment -emergent adverse events (AEs) were dose-dependent, 
reversible thrombocytopenia, anemia, and neutropenia. The above events could increase the risk of infection, including pneumonia and bronchitis, possibility of developi[INVESTIGATOR_370105], bleeding, fatigue, and/or shortness of breath. In healthy volunteers, rheumatoid arthritis patients, and patients with pancreatic cancer or hormone -refractory prostate cancer, the effects on 
hematopoietic proliferation are less pronounced, presumably because of greater bone marrow reserve.  The most frequent non- hematologic AEs were mild, reversible increases in alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST); bruising; hypercholesterolemia; dizziness; headache; and uri nary tract infections. Tuberculosis has been infrequently reported 
in patients receiving ruxolitinib to treat myelofibrosis (<1/100 patients). The symptoms of tuberculosis include chronic cough with blood- tinged sputum, fever, night sweats, and weight 
loss. There may be risks associated with rapid discontinuation of ruxolitinib. 
Patients with myelofibrosis, particularly those who have stopped taking ruxolitinib suddenly, 
have reported return of MF symptoms such as fatigue, bone pain, fever, pruritus, night sweats, 
symptomatic splenomegaly and weight loss. In very few patients, respi[INVESTIGATOR_1506], disseminated intravascular coagulation  (DIC), multiorgan failure have been reported. 
Hepatitis B viral load increases, with and without associated elevations in A LT and AST, have 
been reported in patients with chronic hepatitis B infections taking ruxolitinib. The effect of ruxolitinib on viral replication in patients with chronic  hepatitis B virus is unknown. A rare 
[COMPANY_001]  / Incyte  Confidential  Page 27 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
disease called progressive multifocal leuko -encephalopathy (PML), has been reported with 
ruxolitinib. It is important to note that PML and infections are complications associated with 
MF that has been previously described in the absence of ruxolitinib. Additionally, non-melanoma skin cancers (NMSCs), in cluding basal cell, squamous cell, and a rare and aggressive 
type of skin cancer called m erkel cell carcinoma has been reported in patients who took 
ruxolitinib, it is unknown whether this was due to ruxolitinib treatment. 
In the presence of potent CYP3A4 inhibitors , there is the possibility of increased exposure to 
ruxolitinib  and more frequent monitoring of  hematology parameters is  recommended, although 
no automatic dose adjustment  of ruxolitinib is required . See Appendix [ADDRESS_465259] of cytochrome 
P450 3A4 (CYP3A4) inhibitors and inducers. For a comprehensive assessment of the risks of ruxolitinib, refer to the Investigator Brochure. 
[ADDRESS_465260] meet all  of the following criteria:  
1. Patient or guardian/health proxy must provide informed consent (and assent if applicable) 
before any study assessment is performed. 
2. Male and female patients ag ed ≥ 12 years  (or ≥ the lower age limit allowed by [CONTACT_371928]/or Ethics Committee/Institutional Review Board approvals) . 
3. Patients  with  coronavirus (SARS-CoV-2) infection confirmed by [CONTACT_12036] (PCR) test or another rapid test from the respi[INVESTIGATOR_371896]. 
4. Patient is currently hospi[INVESTIGATOR_371897]. 
5. Patients , who meet at least one of the below criteria : 
• Pulmonary infiltrates (chest X ray or chest CT scan);  
• Respi[INVESTIGATOR_249109] ≥ 30/min; 
• Requiring supplemental oxygen; 
• Oxygen saturation ≤ 94% on room air; 
• Arterial oxygen partial pressure (PaO 2)/ fraction of inspi[INVESTIGATOR_1401] (FiO 2)  
< 300mmHg (1mmHg=0.133kPa) (corrective formulation should be used for higher altitude regions (over 1000m). 
[COMPANY_001]  / Incyte  Confidential  Page 28 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
5.2 Exclusion criteria 
Participants meeting any of the following criteria are not  eligible for inclusion in this study. 
1. History of hypersensitivity to any drugs or metabolites of similar chemical classes as 
ruxolitinib . 
2. Presence of severely impaired renal function defined by [CONTACT_89408] > 2 mg/dL (>176.8 μmol/L), or have estimated creatinine clearance < 30 ml/min measured or calculated by [CONTACT_371925]. 
3. Suspected uncontrolled, active bacterial, fungal, viral, or other infection (besides COVID-19). 
4. Current or history of a ctive TB infection . 
5. History of progressive multifocal leukoencephalopathy ( PML ). 
6. Currently intubated or intubated between screening and randomization. 
7. In intensive care unit (ICU) at time of randomization . 
8. Patients who are on anti- rejection, immunosuppressant or immunomodulatory drugs (i.e. 
tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). 
9. Intubated or in ICU for COVID-[ADDRESS_465261] tablets at randomization. 
12. ALT ≥  [ADDRESS_465262] detected at screening (according to local laboratory reference ranges) . 
13. Patients who have evidence o f liver cirrhosis (Child A to C).  
14. ANC < 1000/ µL at screening . 
15. Platelet count < 50,000/ µL at screening . 
16. Pregnant or nursing (lactating) women. 
17. Females ≥ 12 and < 18 years of age and of childbearing potential (e.g. are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective contraception as defined below, throughout the study and for up to 30 days after stoppi[INVESTIGATOR_056], 
OR 
Females ≥ 18 years of age and of child- bearing potential, defined as all women 
physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception as defined below, throughout the study and for up to 30 days after 
stoppi[INVESTIGATOR_056]. 
Highly effective contraception methods include: 
• Total abstinence (when this is in line with the preferred and usual lifestyle of the 
patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks b efore taking 
study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_104]. 
[COMPANY_001]  / Incyte  Confidential  Page 29 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
• Male sterilization (at least 6 months prior to screening). The vasectomized male 
partner s hould be the sole partner for that patient. 
• Use of oral, injected or implanted hormonal methods of contraception. Placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception (in case of oral contraception, patients should have been using the same pi[INVESTIGATOR_95214] a stable dose for a minimum of 3 months before Screening). 
Women are conside red post -menopausal and not of child bearing potential if they have had 
12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_371929]. 
6 Treatment  
6.1 Study treatment 
6.1.1  Investigational and control drugs  
Ruxolitinib  5 mg tablets or matching placebo will be administered orally twice per day 
approximately 12 hours apart (morning and night) without regards to food. 
Dose reductions or interruptions for any toxicity attributed to study drug are permitted in order 
to allow  the patient to continue on the study treatment. See Section 6.6.2. 
If a patient becomes intubated during the course of the study, study drug can be administered as follows ( Jakafi 2011): 
• For patients unable to ingest tablets, study drug can be administered through a nasogastric tube (8 French or greater) as follows: 
• Suspend one tablet in approximately 40 mL of water with stirring for approximately 10 minutes. 
• Within 6 hours after the tablet has dispersed, the suspension can be administered through a nasogastric tube using an appropriate syringe. 
• The tube should be rinsed with approximately 75 mL of water 
[COMPANY_001]  / Incyte  Confidential  Page 30 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
Table 6-1 Investigational and control drug  
Investigational/ 
Control Drug  Pharmaceutical 
Dosage Form  Route of 
Administration  Supply Type  
INC424 5mg  Tablet  Oral use  Double- blind supply; 
bottles  
INC424 Placebo to 
5mg  Tablet  Oral use  Double- blind supply; 
bottles  
6.1.2  Supply of study treatment  
No additional treatment beyond ruxolitinib 5 mg or matching image placebo will be provided. 
6.1.3  Treatment arms/group  
Participants will be assigned at randomization to one of the following treatment arms/groups in 
a ratio of 2:1: 
• ruxolitinib 5 mg tablets twice daily ; or 
• matching image placebo  tablets twice daily . 
6.1.4  Treatment duration  
The planned duration of treatment is 14 days. An additional 14 days of study drug may be given, 
if in the opi[INVESTIGATOR_871], the patient’s clinical signs and symptoms are not improved 
or worsen and the potential benefit outweighs the potential risk. Participants may be 
discontinued from treatment earlier due to unacceptable toxicity, disease progression a nd/or 
treatment is discontinued at the discretion of the investigator or the participant. Treatment will not be provided upon completion of the study. 
6.2 Other treatments 
6.2.1  Concomitant therapy  
All medications, procedures, and significant non-drug therapi[INVESTIGATOR_014] (including physical therapy and 
blood transfusions) administered after the participant was enrolled into the study must be recorded on the appropriate electronic Case Report Forms (eCRFs) . 
Each concomitant drug must be individually assessed against all exclusion criteria/prohibited medication. If in doubt, the investigator should contact [CONTACT_30791] a participant or allowing a new medication to be started. If the participant is already enrolled, contact [CONTACT_6596]. 
The patient must be told to notify the Treating Physician about any new medications he/she 
takes after the start of study drug. 
[COMPANY_001]  / Incyte  Confidential  Page 31 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
[IP_ADDRESS]  Permitted concomitant therapy requiring caution and/or action  
Patients may receive: anti-virals, inhaled or systemic corticosteroids, heparin, low molecular 
weight heparin (LMWH) , direct oral anticoagulants, anti -emetics, calcineurin inhibitors, azole 
fungal prophylaxis, broad spectrum antibiotics (either semi -synthetic penicillin or third 
generation cephalosporin with vancomycin, gentamycin or equivalent), acyclovir prophylaxis, 
G-CSF, steroid pre -meds prior to RBC/platelet transfusions, narcotics , and sedatives warrant 
close monitoring of potential drug-drug interaction effects of these concurrent drugs. 
Use of oral, injected or implanted hormonal methods of contraception are allowed while on 
study drug. 
In patients  taking warfarin , heparin, LMWH, or direct oral anticoagulants, the degree of 
thrombocytopenia should be considered, platelet counts and coagulation parameters monitored, 
and the dose of anti- coagulant  or non- steroidal anti -inflammatory drug adjusted accordingly. 
In patients taking drugs that affect platelet function/count, the degree of thrombocytopenia should be considered, platelet counts and coagulation parameters monitored, and the dose of 
drug adjusted accordingly. 
In the presence of potent CYP3A4 inhibitors , there is the possibility of increased exposure to 
ruxolitinib  and more frequent monitoring of  hematology parameters is  recommended, although 
no automatic dose adjustment  is required . See Appendix [ADDRESS_465263] of cytochrome P450 3A4 
(CYP3A4) inhibitors and inducers. The patient and the treating physician should be aware of potential signs of overdose of the 
concomitant medications and in the event of suspected study drug related toxicity; administration o f study drug should be dose reduced or held according to the treating 
physician’s judgement. 
For additional information, please refer to the Investigator Brochure. 
6.2.2  Prohibited medication 
The following medications are prohibited until treatment discontinuation: 
• Concomitant use of another JAK inhibitor 
• Aspir in in doses >150 mg/ day 
• Fluconazole > 200 mg daily 
For additional information, please refer to the Investigator Brochure. 
6.3 Participant numbering, treatment assignment, randomization 
6.3.1  Participant numbering 
Each participant is identified in the study by a Participant Number (Participant No.), that is 
assigned when the participant is enrolled for screening and is retained for the participant throughout his/her participation in the trial. The Participant No. consists of the Center Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential participant 
number suffixed to it, so that each participant’s participation is numbered uniquely across the 
[COMPANY_001]  / Incyte  Confidential  Page 32 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
entire database. Upon completion of  informed consent , the participant is assigned to the next 
sequential Participant No. available.  
Screen failures cannot be rescreened. Screen failures should be called into IRT. 
6.3.2  Treatment assignment, randomization  
At the randomization visit, all eligible participants will be randomized via Interactive Response 
Technology (IRT) to one of the treatment arms. The investigator or his/her delegate will contact [CONTACT_6608]/exclusion criteria. The IRT will assign a randomization number to the participant, which will be used to link the participant to a treatment arm and will specify a unique medication number for the first package of study treatment to be dispensed to the participant.  
The randomization numbers will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from participants and investigator staff. A participant randomization list will be produced by [CONTACT_6609] a validated system that automates the random assignment of participant numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers. A separate medication list will b e produced by [CONTACT_6610] (GCS)  using a validated system that automates the random 
assignment of medication numbers to packs containing the study treatment. 
Randomization will be stratified by [CONTACT_371930]. Str atification ensures a balanced allocation of 
subjects to treatment groups within the strata.  
The randomization scheme for subjects will be reviewed and approved by a member of the 
Randomization Office.  
6.4 Treatment blinding 
Participants, investigator staff, p ersons performing the assessments, and CTT will remain blind 
to the identity of the treatment from the time of randomization until database lock, using the following methods: (1) Randomization data are kept strictly confidential until the time of unblinding and will not be accessible by [CONTACT_121927], (2) the identity of 
the treatments will be concealed by [CONTACT_360001], schedule of administration, appearance, taste, and odor. 
Unblinding will occur in the case of participant emergencies and at the conclusion of the study.  
6.5 Dose escalation and dose modification 
Study drug  dose adjustments and/or interruptions are described in Section 6.6.2. 
6.5.1  Dose mo difications  
Dose reductions or interruptions for patients that do not tolerate the dosing schedule and are 
attributed to study drug are permitted in order to allow the patient to continue on the  study 
treatment  (see Section  6.6.2 for more guidance).  
Dose modifications must be reported in the appropriate e CRFs.  
[COMPANY_001]  / Incyte  Confidential  Page 33 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
For subjects with moderate renal impairment (creatinine clearance ( CrCl) 30– 59 mL/min) or any 
level of hepatic impairment, i.e. Mild, Moderate, or Severe (Child-Pugh categories A, B, C), AND 
platelet counts between 50 – 100 X 109 /L, the dose should be reduced to one tablet per day. 
If renal/hepatic impairment AND platelet count improves > 100x 109/L, dosing may be resumed at 
one tablet twice per day . 
[IP_ADDRESS]  Follow up on potential drug- induced liver injury (DILI) cases  
Participants with transaminase increase combined with total bilirubin increase may be 
indicative of potentially severe DILI, and should be considered as clinically important events and assessed appropriately to establish the diagnosis. The required clinical information, as detailed below, should be sought to obtain the medical diagnosis of the most likely cause of the observed laboratory abnormalities.  
The threshold for potential DILI may depend on the participant’s baseline AST/ALT and total bilirubin value; participants meeting any of the following criteria will require further follow -up 
as outlined below: 
• For participants with normal ALT and AST and total bilirubin value at baseline: AST or 
ALT > 3.[ADDRESS_465264] combined with total bilirubin > 2.[ADDRESS_465265] 
• For participants with elevated AST or ALT or total bilirubin value at baseline: [AST or ALT > 2 x baseline]OR [AST or ALT >3 00 U/L]whichever occurs first combined with 
[total bilirubin > 2 x baseline AND > 2.[ADDRESS_465266]] 
As DILI is essentially a diagnosis of exclusion, other causes of abnormal liver tests should be considered and their role clarified before DILI is assumed as the cause of liver injury. 
A detailed history, including relevant information such as review of ethanol consumption, 
concomitant medications, herbal remedies, supplement consumption, history of any pre -
existing liver conditions or risk factors, should be collec ted. 
Laboratory tests should include ALT, AST, total bilirubin, direct and indirect bilirubin, GGT, GLDH (if available  at local laboratory ), prothrombin time (PT)/INR, alkaline phosphatase, 
albumin, and creatine kinase. 
6.6 Additional treatment guidance 
6.6.1  Treatm ent compliance  
Treatment will be recorded on the appropriate e CRF.  
6.6.2  Recommended treatment of adverse events 
Dose reductions or interruptions for patients that do not tolerate the dosing schedule and are attributed to study drug are permitted in order to allow the patient to con tinue on the study 
treatment . Adverse events will be assessed and graded according to the Common Terminology 
Criteria for Adverse Events (CTCAE) V ersion  5.0 as described in Section 10.1.1. 
Neutropenia  (Growth factor supplementation and transfusion should be provided as clinically 
indicated.) 
[COMPANY_001]  / Incyte  Confidential  Page 34 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
Grade 3 (ANC <  750 - 500/mm3): Reduce dose to one tablet per day , monitor ANC daily until 
resolved to ≤ Grade 2, then resume initial dose level.  
Grade 4 (ANC < 500/mm3): Hold dose, monitor ANC daily until resolved to ≤  Grade 3, then 
resume with  reduced dose of  one tablet per day . If resolves to ≤  Grade 2,  can resume initial 
dose level.  
Thrombocytopenia (transfusion support should be provided as cli nically indicated)  
For platelet counts < 20,000/ mm3: Hold dose until resolved to > 35,000/mm3, then resume at 
a reduced dose level  of one tablet per day . If counts are stable, dose may be cautiously re -
escalated.  
Dose reductions or interruptions for non-he matologic toxicity are permitted in order to allow 
the patient to continue on the study treatment. Dose adjustments for different ranges of non-
hematologic toxicity are described below. The objective of the dose adjustment rules is to optimize treatment re sponse for each individual patient while avoiding significant non-
hematologic toxicities.  
AST/ALT elevation 
See Appendix 1 for s toppi[INVESTIGATOR_371898]/AST.  
Other adverse events (non -hematological) attributed to study drug 
Recommendation for Grade 1 or 2: M aintain dose level . 
Grade 3: Hold dose until resolved to baseline or Grade 1 . 
Grade 4: Discontinue from study treatment. 
Medication used to treat adverse events (AEs) must be recorded on the appropriate eCRF. 
6.6.[ADDRESS_465267] the participant’s next treatment regimen, and after discussion and agreement with the [COMPANY_001] . Most often, study 
treatment discontinuation and knowledge of the possible treatment assignme nts are sufficient 
to treat a study participant who presents with an emergency condition. Emergency treatment code breaks are performed using the IRT. When the investigator contacts the system to break a treatment code for a participant, he/she must provide the requested participant identifying information and confirm the necessity to break the treatment code for the participant. The investigator will then receive details of the investigational drug treatment for the specified participant and a fax or email confirming this information. The system will automatically inform 
the [COMPANY_001] monitor for the site and the study team that the code has been broken. 
It is the investigator’s responsibility to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency. The investigator will provide: 
• protocol number 
• participant number 
[COMPANY_001]  / Incyte  Confidential  Page 35 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
In addition, oral and written information to the participant must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency, or when he/she is unavailable, to ensure that un-blinding can be performed at any time.  
6.7 Preparation and dispensation 
Each study site will be supplied with study drug in packaging as described under investigational 
and control drugs section. 
A unique medication number is printed on the study medication label. 
6.7.1  Handling of study treatment and additional treatment  
[IP_ADDRESS]  Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly and kept in a secured location to which only the investigator and designated site personnel have access. Upon receipt, all study treatment must be stored according to the instructions specified in the Investigator’s Brochure. 
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints 
are to be reported to the respective [COMPANY_001]  CO Quality Assurance.  
Medication labels will be in the local language and comply with the legal requirements of each 
country. They will include storage conditions for the study treatment but no information about the participant except for the medication number . 
The investigator must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Monitoring of drug accountability will be performed by [CONTACT_30798]. Participants will be asked to return all unused study treatment and packaging at the end of the study or at the time of discontinuation of study treatment. 
At the conclusion of the study, and as appropriate during the course of the study, the investigator 
will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site or destroyed as per local regulation. 
7 Informed consent procedures  
Eligible participants may only be included in the study after providing (witnessed, where required by [CONTACT_6617]), IRB/IEC-approved informed consent. 
If applicable, in cases where the participant’s representative(s) gives consent (if allowed 
according to local requirements), the participant  must be informed about the study to the extent 
possible given his/her understanding. If the participant  is capable of doing so, he/she must 
indicate agreement by [CONTACT_371931]. 
Informed consent must be obtained before conducting any study- specific procedures (e.g. all of 
the procedures described in the protocol). The  process of obtaining informed consent must be 
documented in the participant source documents. 
[COMPANY_001]  / Incyte  Confidential  Page 37 of 74 
Amended Protocol Version 01 ( Clean)  Protocol No. CINC424J12301  
 
• Efficacy assessments: clinical status, clinical signs and symptoms, oxygen saturation, 
consciousness, ventilatory status ; 
• Safety assessments: vital signs, review of adverse events, concomitant medications; 
Laboratory samples: on days indicated in schedule of assessments.  
Results from tests or examinations done as part of routine care prior to the screening visit may be used for the study as indicated in Table 8 -1 (Assessment Schedule). However, the above-
mentioned efficacy assessments (clinical  status, clinical signs and symptoms, oxygen 
saturation, consciousness, ventilatory status) must be done  in the morning of 
randomization between 7 AM and 12 PM, prior to administering study drug.  
If a patient is discharged  from the hospi[INVESTIGATOR_371899], the Clinical Status 
Evaluation with 9- point ordinal scale will be performed via telephone call ( between 7 AM and 
12 PM local time) daily except for Day  15 and Day 29 when it will be performed in clinic.  For 
Day 15 and Day 29, i f an in -clinic visit is not possible, the visit may be performed in an 
appropriate setting, including at home, with appropriate study personnel. 
[COMPANY_001]  / Incyte  Confidential  Page 38 of 74 
Amended Protocol Version 01 (Clean)  Protocol No. CINC424J12301  
 
 Table 8-1 Assessment Schedule  
All assessments will be obtained while patient is in hospi[INVESTIGATOR_307]. Once patient is discharged, assessments will be done via the telephone as indicated 
in the table below with the exception of Day 15 and Day 29 which require in- clinic assessments.  For Day 15 and Day 29, i f an in -clinic visit 
is not possible, the visit may be performed in an appropriate setting, including at home, with appropriate study personnel. 
 
 Screening  Study Period  
Study Day  Screening  Day 1  
(Randomization ) Day 2-14  
(every day 
unless otherwise 
specified below)  Day 15  Day 16-28 
(every day 
unless 
otherwise 
specified below)  Day 29  
(End of 
study)  
Informed consent (and assent if applicable)1 x      
Inclusion  / Exclusion criteria  x x     
Demographics / medical history  (including co -morbidities 
checklist)  x      
SARS -CoV-2 virus confirmation2 s      
Vital signs3 
(between 7 AM and 12 PM  local time)  x4 x x 
(while in hospi[INVESTIGATOR_307])  x x 
(while in hospi[INVESTIGATOR_307])  x 
SpO 2 assessment  
(between 7 AM and 12 PM  local time – done at same 
time as vital signs)  x4 x x  
(while in hospi[INVESTIGATOR_307])  x x 
(while in hospi[INVESTIGATOR_307])  x 
SpO 2 assessment on room air (for patients on oxygen by  
[CONTACT_371932] ( ≤ 2L/min)  (based on investigator medical 
judgement)  
(between 7 AM and 12 PM  local time – done at same 
time as vital signs)    (only on day of 
discharge)  x (only on day of 
discharge)  x 
FiO 2 assessment  
(between 7 AM and 12 PM  local time – done at same 
time as vital signs)  x4 x x 
(while in hospi[INVESTIGATOR_307])  x x 
(while in hospi[INVESTIGATOR_307])  x 
[COMPANY_001]  / Incyte  Confidential  Page 40 of 74 
Amended Protocol Version 01 (Clean)  Protocol No. CINC424J12301  
 
  Screening  Study Period  
Study Day  Screening  Day 1  
(Randomization ) Day 2-14  
(every day 
unless otherwise 
specified below)  Day 15  Day 16-28 
(every day 
unless 
otherwise 
specified below)  Day 29  
(End of 
study)  
Serum pregnancy test (local labs) ; results must be 
reviewed prior to randomization x8     x 
Chest x -ray (CXR) or chest CT scan9 x      
ECG (local)4 s      
Adverse events  x x x 
(via telephone if 
not in hospi[INVESTIGATOR_307])  x x 
(via telephone if 
not in hospi[INVESTIGATOR_307])  x 
Prior and c oncomitant non- drug therapi[INVESTIGATOR_014] (including 
surgeries and procedures)  x x x 
(via telephone if 
not in hospi[INVESTIGATOR_307])  x x 
(via telephone if 
not in hospi[INVESTIGATOR_307])  x 
Prior/concomitant medications  x x x 
(via telephone if 
not in hospi[INVESTIGATOR_307])  x x 
(via telephone if 
not in hospi[INVESTIGATOR_307])  x 
In-hospi[INVESTIGATOR_95209]10 x x x 
(while in hospi[INVESTIGATOR_307])  x x 
(while in hospi[INVESTIGATOR_307])  x 
Contact [CONTACT_12067]11 x x     

[COMPANY_001]  / Incyte  Confidential  Page 41 of 74 
Amended Protocol Version 01 (Clean)  Protocol No. CINC424J12301  
 
  Screening  Study Period  
Study Day  Screening  Day 1  
(Randomization ) Day 2-14  
(every day 
unless otherwise 
specified below)  Day 15  Day 16-28 
(every day 
unless 
otherwise 
specified below)  Day 29  
(End of 
study)  
1. Informed consent must be obtained prior to any study -related procedure.  
2. SARS-CoV -2 virus to be measured by [CONTACT_940] (PCR) test or another rapid test from the respi[INVESTIGATOR_371881] (may use test 
done as part of routine care prior to screening). If no SARS -CoV -[ADDRESS_465268] should be obtained at screening.  
3. Vital signs include pulse rate, respi[INVESTIGATOR_697] (if not on mechanical ventilation), systolic and diastolic blood pressure and body temperature.  
4. Results from tests or examinations done as part of routine care and performed up to [ADDRESS_465269]: Only for females of childbearing potential, serum pregnancy test (serum hCG).  Pregnancy tests done as part of routine care up to [ADDRESS_465270] scan prior to randomization (may use chest X -ray or chest CT done as part of routine care prior to screening). If no chest X -ray or chest CT 
scan available from routine care, chest X -ray or chest CT scan should be obtained at screening.  
10. In-hospi[INVESTIGATOR_371900] . 
11. Screen failures must be called into IRT.  
(s) = assessment to be recorded in source documents only; assessment will not be entered into the eCRFs ; 
(x) = assessment to be recorded  in source documents and entered into the eCRF  

[COMPANY_001]  / Incyte  Confidential  Page 42 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 8.1 Screening 
No rescreening  will be allowed.  
8.1.1  Information to be collected on screening failures  
Participants who sign an informed consent form and subsequently found to be ineligible prior 
to randomization will be considered a screen failure. The reason for screen failure should be 
recorded on the appropriate Case Report Form. The demographic information, informed 
consent, and Inclusion/Exclusion pages must also be completed for screen failure participants. No other data will be entered into the clinical database for participants who are screen failures, unless the participant experienced a serious adverse event during the screening phase ( see 
Section 10.1.3 for reporting details). If the participant fails to be randomized, the IRT must be 
notified within 2 days of the screen fail that the participant was not randomized.  
Participants who are randomized and fail to start treatment, e.g. participants randomized in error, will be considered an early terminator. The reason for early termination should be recorded on the appropriate Case Report Form.  
8.2 Participant demographics/other baseline characteristics 
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with e CRF.  
Participant race and ethnicity are collected and analyzed to identif y variations in safety or 
efficacy due to these factors as well as to assess the diversity of the study population as required by [CONTACT_6628]. 
8.3 Efficacy 
8.3.1  Clinical status ( 9-point ordinal scale)  
Assessment of clinical status using a 9- category ordinal scale ( WHO 18-Feb-2020) will be 
recorded at baseline on Day  1 and then again once daily every morning (between 7AM and 
12PM ) through Day 29 of the Study Period. If a patient is discharged from the hospi[INVESTIGATOR_307], the 
assessment will be made by [CONTACT_648] ( between 7 AM and 12PM ). Each day, the worse score for 
the previous day will be recorded, i.e . on Day 3, Day 2 score is obtained and recorded as Day 
2. The scale is as follows:  
Table 8-2 Clinical status 9- category ordinal scale  
Patient State  Descriptor  Score  
Uninfected  No clinical or virological evidence of infection  0 
Ambulatory  (defined as 
not in hospi[INVESTIGATOR_371901])  No limitation of activities  1 
Limitation of activities  2 
Hospi[INVESTIGATOR_371902], no oxygen therapy  (defined as SpO 2 ≥ 94% on 
room air)  3 
Oxygen by [CONTACT_88543]  4 
[COMPANY_001]  / Incyte  Confidential  Page 43 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 Patient State  Descriptor  Score  
Hospi[INVESTIGATOR_371903]-invasive ventilation or high -flow oxygen  5 
Intubation and mechanical ventilation  6 
Ventilation + additional organ support – pressors, RRT  (renal 
replacement therapy), ECMO (extracorporeal membrane 
oxygenation)  7 
Dead  Death  8 
8.3.2  Vital signs and oxygen saturation  
Results from tests or examinations done as part of routine care may be used as specified in the 
table of assessments (See Table 8 -1). 
Vital sign measurement include respi[INVESTIGATOR_697], pulse rate, systolic and diastolic blood pressure, and body temperature. Peripheral oxygen saturation (SpO
2) should also be measured at the same 
time as the vitals. For patients on oxygen by [CONTACT_21294] ( ≤ 2L/min), SpO 2 assessment on 
room air (based on investigator medical  judgement) will also be performed at the same time as 
the vitals  on Days 15, 29 and at discharge . For patients requiring supplemental oxygen, the 
oxygen flow rate (L/min) and/or fraction of inspi[INVESTIGATOR_1401] (FiO 2) should be recorded at the 
same time as the vitals . 
In order to a llow assessment of the NEWS2  score ( Appendix 3), the vital sign parameters and 
oxygen saturation should be recorded together once per day ( between 7 AM and 12PM ), for the 
duration of the hospi[INVESTIGATOR_16366]. Following hospi[INVESTIGATOR_371904] 15 and 29. 
8.3.3  National Early Warning Score  2 (NEWS 2) 
In addition to the vital signs, the patient’s level of consciousness and the presence/absence of 
respir atory support must be recorded. The NEWS2  parameter for respi[INVESTIGATOR_371905] “oxygen” can include other forms of ventilation to maintain oxygen 
saturation (see Appendix 3).  
These should be recorded at the same time points as the vital sign measurements  
(between 7 AM and 12 PM)  (see Section 8.3.2).  
NEWS2  values will be calculated electronically by  [CONTACT_371933] s ign parameters and 
NEWS2  related assessments recorded by [CONTACT_371934]. 
8.3.4  In-hospi[INVESTIGATOR_371906], the following in hospi[INVESTIGATOR_371907]: 
• Start and end date of mechanical ventilation  
• Start and end date of hospi[INVESTIGATOR_371908]  / Incyte  Confidential  Page 44 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 8.3.5  Ventilatory status  
Ventilatory status (mechanical ventilation, supplemental oxygen, intubation and non-invasive 
ventila tion [e.g. CPAP, BI PAP, etc.])  will be collected at  timepoints designated in Table 8 -1 
and recorded by [CONTACT_249169] s. 
8.3.6  Appropriateness of efficacy assessments  
Efficacy endpoints are those employed in other studies of patients with C OVID -19 pneumonia 
(WHO 2020; Cao et al 202 0). 
8.4 Safety 
Safety assessments are specified below with the assessment schedule detailing when each assessment is to be performed.  
For details on AE collection and reporting, refer to Section 10.1.1. 
8.4.1  Laboratory evaluations  
Laboratory evaluations will be performed by a local lab oratory . Results from tests or 
examinations done as part of routine care may be used as specified in the table of assessments 
(See Table 8 -1). 
Hematology  
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, and  
platelet count will be measured according to the assessment schedule in Table 8 -1. 
Chemistry  
BUN/urea, creatinine, creatine kinase, total bilirubin, AST, ALT, alkaline phosphatase, sodium, potassium, chloride, calcium, bicarbonate , total protein, albumin,  and glucose will be measured 
according to the assessment schedule in Table [ADDRESS_465271] reacting bilirubin.  
 
  
  
  
  
  
Sample(s) will be collected at the time point(s) defined in the Assessment Schedule  
(Table 8 -1). If a given test is not available  locally, this should be documented on the e CRF.  

[COMPANY_001]  / Incyte  Confidential  Page 45 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 Drug -induced liver injury monitoring  
For patients with elevated liver tests, additional laboratory tests as denoted in Appendix 1  
(Table 16 -1, Table 16 -2 and Table 1 6-3) should be obtained as specified. 
8.4.[ADDRESS_465272] be included in the Relevant Medical History/Current Medical Conditions screen on the patient’s eCRF. Significant findings made after informed consent is given which meet the definition of an Adverse Event must be recorded on the Adverse Event screen of the patient’s eCRF.  
8.4.3  Height, weight, BMI  
Results from tests or examinations done as part of routine care may be used as specified in the table of assessments (See Table 8 -1). 
If possible, h eight will be measured at the Screening visit as specified in the table of assessments 
(See Table 8 -1). Otherwise, patient or guardian/health proxy reported height will be obtained. 
Body weight will be measured at the Screening visit as specified in the table of assessments (See Table 8 -1). 
Body Mass Index (BMI) will be calculated as the weight in kg divided by [CONTACT_371935]. 
8.4.4  Electrocardiogram (ECG)  
Results from tests or examinations done as part of routine care may be used as specified in the 
table of assessments (See Table 8 -1). 
An ECG will be taken at Screening  and recorded in source documents. 
The ECG should be recorded after [ADDRESS_465273] in the supi[INVESTIGATOR_188597] a stable baseline.  
Clinically significant abnormalities should be recorded on the relevant section of the medical history/Current medical conditions/AE eCRF page as appropriate.  
If necessary, a cardiologist may be consulted. 
8.4.5  Pregnancy and assessments of fertility  
Results from tests or examinations done as part of routine care may be used as specified in the 
table of assessments (See Table 8 -1). 
All women of child bearing potential w ill have a serum pregnancy test at Screening and  at 
designated visits ( Table 8 -1). 
[COMPANY_001]  / Incyte  Confidential  Page 46 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 A positive pregnancy test at any time will result in study discontinuation. 
8.4.6  Appropriateness of safety measurements  
The safety assessments selected are appropriate for this protocol which utilizes a marketed 
compound where the safety profile has been established. The assessments are relevant to the critical care setting and will enable determination of therapeutic response in this  setting.  

[COMPANY_001]  / Incyte  Confidential  Page 47 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 [ADDRESS_465274] discontinue study treatment for a given participant if, he/she believes that 
continuation would negatively impact the participant's well-being. 
Study treatment must be discontinued under the following circumstances: 
• Participant/guard ian decision 
• Pregnancy  
• Use of prohibited treatment as per recommendations in the prohibited treatment section  
• Abnormal liver laboratory results as specified in Appendix 1 
• Grade 4 non-hematologic adverse events attributed to study drug 
• Any situation in which study participation might result in a safety risk to the participant 
• Following emergency unblinding 
• Any laboratory abnormalities that in the judgment of the investigator, taking into 
consideration the participant’s overall status , prevents the participant from continuing 
participation in the study 
If discontinuation of study treatment occurs, the investigator should make a reasonable effort to understand the primary reason for the participant’s premature discontinuation of study treatment and record this information. 
Participants who discontinue study treatment or who decide they do not wish to participate in 
the study further should NOT be considered withdrawn from the study UNLESS they withdraw their c onsent (see 'Withdrawal of Informed Consent' section). Where possible, they should 
return for the assessments indicated in the Assessment Schedule. If they fail to return for these assessments for unknown reasons, every effort (e.g. telephone, e -mail, letter) should be 
made to contact [CONTACT_2299]/pre- designated contact [CONTACT_49425] -up 
section. This contact [CONTACT_6636]. 
If the participant cannot or is unwilling to attend any visit( s), the site staff should maintain 
regular telephone contact [CONTACT_6635], or with a person pre -designated by [CONTACT_2299]. 
This telephone contact [CONTACT_6636]. After study treatment discontinua tion, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:  
• New / concomitant treatments  
• Adverse Events / Serious Adverse Events 
The investigator must also contact [CONTACT_6637]’s discontinuation from 
study treatment.  
[COMPANY_001]  / Incyte  Confidential  Page 48 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 If discontinuation occurs because treatment code has been broken, please refer to Emergency 
breaking of treatment code section.  
9.1.2  Replacement policy  
Patients discontinuing the study will not be replaced. 
9.1.3  Withdrawal of informed consent  
Participants may voluntarily withdraw consent to participate in the study for any reason at any 
time. Withdrawal of consent occurs only when a participant: 
• Does not want to participate in the study anymore, 
and 
• Does not want any further visits or assessments 
and 
• Does not want any further study related contacts 
In this situation, the investigator should make a reasonable effort to understand the primary 
reason for the participant’s decision to withdraw his/her consent and record this information.  
Where consent to the use of personal and coded data is not required, participant therefore cannot withdraw consent. They still retain the right to object to the further use of personal data. 
Study treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_30814]-up. 
All efforts should be made to complete the assessments prior to study discontinuation. A final 
evaluation at the time of the participant’s study discontinuation should be made as detailed in 
the assessment table.  
[COMPANY_001] will continue to retain and use all re search results (data) that have already been 
collected for the study evaluation. 
9.1.[ADDRESS_465275] show "due diligence" by [CONTACT_6638], e.g. dates of telephone calls, registered letters, etc. A participant should not be considered as lost to follow -
up until due diligence has been completed or until the end of the study.  
9.1.5  Early study termination by [CONTACT_30815].  
[COMPANY_001]  / Incyte  Confidential  Page 49 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 Reasons for early termination : 
• Unexpected, significant, or unacceptable safety risk to participants enrolled in the study 
• Deci sion based on recommendations from applicable board(s) after review of safety and 
efficacy data  
• Discontinuation of study drug development 
In taking the decision to terminate, [COMPANY_001]  will always consider participant welfare and safety. 
Should early termination be necessary, participants must be seen as soon as possible  and treated 
as a prematurely withdrawn participant. The investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the protection of the participant’s interests. The investigator or sponsor depending on local 
regulation will be responsible for informing IRBs/IECs of the early termination of the trial.  
9.[ADDRESS_465276] been documented and followed-up appropriately by [CONTACT_29517], in the event of an early study termination decision, the date of that decision (e.g. Each participant will be required to complete the study in its entirety and 
thereafter no further study treatment will be made available to them).  
10 Safety monitoring and reporting 
10.1 Definition of adverse events and reporting requirements 
10.1.1  Adverse events  
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. 
Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. 
The investigator has the responsibility for managing the safety of individual participant and 
identifying adverse events. 
[COMPANY_001] qualified medical personnel will be readily available to advise on trial related medical 
questions or problems. 
The occurrence of adverse events must be sought by [CONTACT_105]- directive questioning of the participant 
at each visit during the study. Adverse events also may be detected when they are volunteered 
by [CONTACT_6643], laboratory test findings, or other assessments. 
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, 
accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to 
Section 10.1.3):  
[COMPANY_001]  / Incyte  Confidential  Page 50 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 1. Adverse events will be assessed and graded according to the Common Terminology 
Criteria for Adverse Events (CTCAE) V ersion  5.0. 
2. Its relationship to the study treatment. If the event is due to lack of efficacy or progression of underlying illness (i.e. progression of the study indication) the assessment of causality will usually be ‘Not suspected.’ The rationale for this guidance is that the symptoms of a lack of efficacy  or progression of underlying illness are not caused by [CONTACT_6645], they 
happen in spi[INVESTIGATOR_6532]/or both lack of efficacy and progression of underlying disease can only be evaluated meaningfully by [CONTACT_6646], not on a single participant  
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not resolved must be reported 
4. Whether it constitutes a SAE (see Section 10.1.3 for definition of SAE) and which seriousness criteria have been met  
5. Action taken regarding with study treatment. 
All adverse events must be treated appropriately. Treatment may include one or more of the following: 
• Dose not changed 
• Dose Reduced/increased  
• Drug interrupted/withdrawn 
6. Its outcome (i.e. recovery status or whether it was fatal)  
Conditions that were already present at the time of informed consent should be recorded in medical history of the participant.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Once an adverse event is detected, it must be followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study), and assessment must be made at each 
visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the interventions required to treat it, and the outcome. 
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator's Brochure (IB). 
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria: 
• they induce clinical signs or symptoms 
• they are considered clinically significant  
• they require therapy  
[COMPANY_001]  / Incyte  Confidential  Page 51 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 10.1.2  Serious adverse events 
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following 
criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to the ICH -E2D Guidelines). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]: 
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition 
• elective or pre- planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
• social reasons and respi[INVESTIGATOR_6534]’s general condition 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
• is medically significant, e.g. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientifi c judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_371909]. Such events should be considered as “medically significant.” Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_6536]  (please refer to the ICH-
E2D Guidelines ). 
All new malignant neoplasms will be assessed as serious under “medically significant” if other seriousnes s criteria are not . 
Any suspected transmission via a medicinal product of an infectious agent is also considered a serious adverse reaction.  
All reports of intentional misuse and abuse of the product are also considered serious adverse event irrespective i f a clinical event has occurred.  
[COMPANY_001]  / Incyte  Confidential  Page 52 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 10.1.[ADDRESS_465277] be reported to [COMPANY_001] safety 
within 24 hours of learning of its occurrence. Detailed instructions regarding the submission process and requirements are to be found in the investigator folder provided to each site. 
Screen Failures (e.g. a participant who is screened but is not treated or randomized) : SAEs 
occurring after the participant has provided informed consent until the time the participant is 
deemed a Screen Failure must be reported to [COMPANY_001]. 
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occur rence) and is thought to be related to the study treatment, a CMO & PS Department 
associate may urgently require further information from the investigator for health authority reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study with the same study treatment that this SAE has been reported. 
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees  in accordance with EU Guidance 
2011/C 172/[ADDRESS_465278] be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded and reported by [CONTACT_371936] (CMO&PS). Pregnancy follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study treatment any 
pregnancy outcome. Any SAE experienced during pregnancy must be reported. 
10.1.5  Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, participant or consumer (EMA definition). 
Misuse refers to situations where the medicinal product is intentionally and inappropriately used 
not in accordance with the protocol. 
[COMPANY_001]  / Incyte  Confidential  Page 53 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied by [CONTACT_3584]. 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate e CRF irrespective of whether or not associated with an AE/SAE and reported 
to Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator’s awareness.  
Table 10 -1 Guidance for capturing the study treatment errors including 
misuse/abuse  
Treatment error type  Document in Dosing 
eCRF (Yes/No)  Document in AE 
eCRF  Complete SAE form  
Unintentional study 
treatment error  Yes Only if associated with 
an AE  Only if associated with 
an SAE  
Misuse/Abuse  Yes Yes Yes, even if not 
associated with a SAE  
For more information on AE and SAE definition and reporting requireme nts, please see the 
respective S ections. 
10.2 Additional Safety Monitoring 
Not applicable.  
10.2.1  Liver safety monitoring  
To ensure participant safety and enhance reliability in determining the hepatotoxic potential of 
an investigational drug, a standardized process for identification, monitoring and evaluation of liver events has to be followed. 
Please refer to Appendix 1 for complete definitions of liver laboratory triggers. Once a participant is exposed to study treatment, every liver event defined in Table 16 -1 should 
be followed up by [CONTACT_6648], as summarized below. 
Additional details on actions required in case of liver events are outlined in Table 16 -2 and 
Table 16 -3. Repeat liver chemistry tests (i.e. ALT, AST, TBL, PT/INR, ALP and G -GT) to 
confirm elevation.  
These liver chemistry repeats should be performed using the local laboratory used by [CONTACT_779]. Repeated laboratory test results must be reported as appropriate.  
• If the initial elevation is confirmed, close observation of the participant will be initiated, including consideration of treatment interruption if deemed appropriate. 
• Discontinuation of the investigational drug (refer to the Discontinuation of study treatment Section 9.1), if appropriate 
• Hospi[INVESTIGATOR_6539]  
• Causality assessment of the liver event  
• Thorough follow-up of the liver event should include 
[COMPANY_001]  / Incyte  Confidential  Page 54 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 • These investigations can include based on investigator’s discretion: serology tests, 
imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease 
All follow -up information and procedures performed must be recorded as appropriate in the 
eCRF.  
10.2.2  Data Monitoring Committee  
This study will include a n internal  data monitoring committee (DMC) which will function 
independently of all other individuals associated with the conduct of this clinical trial, including the site investigators participating in the study. 
Specific details regarding composition, responsibilities, data monitoring, and meeting 
frequency, and documentation of DMC reports, minutes, and recommendations will be described in a separate charter.  
[ADDRESS_465279] that allows its accurate reporting, interpretatio n, and verification. 
Designated investigator staff will enter the data required by [CONTACT_371937] ( Table 8 -1) into the Electronic Case Report Forms (eCRF). The eCRFs 
have been bu ilt using fully validated secure web- enabled software that conforms to [ADDRESS_465280] been trained. Automatic validation programs check for data discrepancies in the eCRFs, allow modification and/or verification of the entered data by [CONTACT_6649]. 
The investigator/designee is responsible for assuring that the data (recorded on eCRFs) (entered 
into eCRF) is complete, accurate, and that entry and update s are performed in a timely manner. 
The Investigator must certify that the data entered are complete and accurate.  
This study may also incorporate electronic technology (eSource DDE) to capture source documents and source data electronically, consistent with final (CDER 2013) FDA guidance regarding electronic source and regulations related to the maintenance of adequate participant case histories (21 CFR 312.62 [b]). 
A [COMPANY_001] representative will review the protocol and data capture requirements (i.e. eSource 
DDE and/or eCRFs) with the investigators and their staff. 
After final database lock, the investigator will receive copi[INVESTIGATOR_157052].  
[COMPANY_001]  / Incyte  Confidential  Page 55 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 11.2 Database management and quality control 
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432]. Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly to queries and to make any necessary changes to the data. 
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Medical history/current medical conditions and adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Dates of screenings, randomizations, screen failures and study completion, as well as 
randomization codes and data about all study treatment (s) dispensed to the participant and all dosage changes will be tracked  using an Interactive Response Technology (IRT). The system 
will be supplied by a vendor, who will also manage the database. The data will be sent electronically to [COMPANY_001] (or a designated CRO) at specific timelines.  
Each occurrence of a code break via I RT will be reported to the clinical team and monitor. The 
code break functionality will remain available until study shut down or upon request of [COMPANY_001] . 
Once all the necessary actions have been completed and the database has been declared to be complete  and accurate, it will be locked and the treatment codes will be unblinded and made 
available for data analysis/moved to restricted area to be accessed by [CONTACT_49433] . Any changes to the database after that time can only be made  after written 
agreement by [CONTACT_188660].  
11.3 Site monitoring 
Before study initiation, at an initiation visit or at an investigator’s meeting, a [COMPANY_001] representative will review the protocol and data capture requirements (i.e. eSource DDE and/or eCRFs) with the investigators and their staff. During the study, Nova rtis employs several 
methods of ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will check the completeness of participant records, the  accuracy of data 
capture / data entry, the adherence to the protoco l and to Good Clinical Practice, the progress 
of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor in conducting the se activities. Continuous  monitoring of each site’s data will be performed 
throughout the conduct of the study. Additionally, a central analytics organization may analyze data & identify risks & trends for site operational parameters, and provide reports to [COMPANY_001] clinical teams to assist with trial oversight.  
The investigator must maintain source documents for each participant in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical informatio n, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on e CRFs must be traceable to the respective source documents.   
[COMPANY_001]  / Incyte  Confidential  Page 56 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 The investigator must also keep the original informed consent form signed by [CONTACT_371938]/or legal representative (a signed cop y is given to the participant). 
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. Source data verification m ay be done on-
site, if possible, or remotely, if the field monitor does not have access or have limited access to the site due to the current COVID -[ADDRESS_465281] adhere to the recommendations established by [CONTACT_371939]. [COMPANY_001] monitoring standards require verification for the presence of all informed consents, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the eCRFs ar e performed according to the study- specific monitoring plan. No information in source 
documents about the identity of the participants will be disclosed. 
12 Data analysis and statistical methods 
Any data analysis carried out independently by [CONTACT_30817]. 
12.1 Analysis sets  
The Randomized Analysis Set (RAS) consists of all randomized participants. 
According to the intent to treat principle, participants will be analyzed according to the 
treatmen t they have been assigned to during the randomization procedure. 
The Safety Set includes all participants who received at least one dose of study treatment. 
Participants will be analyzed according to the study treatment received , where treatment 
received is defined as the randomized/assigned treatment if the participant took at least one dose 
of that treatment or the first treatment received if the randomized/assigned treatment was never received.  
The analysis of the primary objective and all other efficacy variables will be performed on the RAS. The Safety Set will be used in the analysis of all safety variables.  
12.[ADDRESS_465282] deviation, median, minimum, and maximum will be presented. For sele cted parameters, 
25th and 75th percentiles will also be presented. 
Relevant medical histories and current medical conditions at baseline will be summarized by 
[CONTACT_6657], by [CONTACT_1570]. 
[COMPANY_001]  / Incyte  Confidential  Page 57 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 12.[ADDRESS_465283] of care therapi[INVESTIGATOR_371910] S afety set.  
Concomitant medications and significant non- drug therapi[INVESTIGATOR_371911] d summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification system, by [CONTACT_1570] . 
12.4 Analysis of the primary endpoint(s)/estimand(s) 
The primary analysis for this study will be conducted on the R AS according the intention to 
treat principle. 
12.4.1  Definition of primary endpoint(s)/estimand(s)  
The estimand framework for the primary objective is as follows: 
• Treatment – ruxolitinib added to SoC therapy 
• Population – Hospi[INVESTIGATOR_371912] (SARS -CoV-2) infection confirmed by 
[CONTACT_940] (PCR) test or another rapid test from the respi[INVESTIGATOR_371913] 5.1. 
• Endpoint – Primary efficacy endpoint is clinical failure, defin ed as the occurrence of death, 
respi[INVESTIGATOR_1399] (require mechanical ventilation), or ICU care by [CONTACT_2006] 29. 
• Population- level summary –  Odds- ratio comparing ruxolitinib added to  SoC therapy to 
placebo added to  SoC therapy. 
• Intercurrent event (s) – Discontinuation  of study treatment 
12.4.2  Statistical model, hypothesis, and method of analysis  
The statistical hypothesis tested for clinical failure is that there is no difference in the proportion of subjects developi[INVESTIGATOR_371914] 29 with ruxolitinib + SoC versus placebo + SoC therapy. 
Let p
i denote the proportion of clinical failures by [CONTACT_2006] 29 for treatment groups j, j = 0, 1 where  
• 0 corresponds to placebo + SoC 
• 1 corresponds to ruxolitinib + SoC 
The following statistical hypothesis will be tested to address the primary objective:  
H0: p0 = p 1, H1: p0 ≠ p 1. 
The odds of clinical failure will be analyzed by a logistic regress ion model with treatment group, 
region (North America, Europe), baseline clinical status  based on the 9 -point ordinal scale  (≤4, 
≥5), age, and gender as covariates. The estimated odds ratio, p -values, and 95% confidence 
intervals will be presented. 
The study will be considered positive, if ruxolitinib demonstrates a statistically significant 
greater reduction in clinical failure . This implies observing an odds ratio of < 1. 
[COMPANY_001]  / Incyte  Confidential  Page 58 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 12.4.3  Handling of remaining intercurrent events of primary estimand  
Discontinuation of study treatment for any reason: Retrieved drop out (RDO) data after 
study treatment discontinuation will be collected. If RDO data is available up to D ay 29 this 
will be used for analysis . If no RDO data was collected after study treatment  discontinuation or 
the RDO data is not complete to D ay 29  then the patient will be considered as a clinical failure, 
unless they are in one of the scenarios below: 
• There was no occurrence of death, mechanical ventilation, nor ICU care in all the 
available data and patients were discharged from the hospi[INVESTIGATOR_307]  
• The last available data (either on -treatment or off -treatment) is from Day 15 or later, and 
there was no occurrence of death, mechanical ventilation, nor ICU care in all the available 
data 
12.4.4  Handling of missing values not related to intercurrent event  
For patients who withdraw from the study, their clinical failure status will be handled similarly as in Section 12.4.3. Other missing data handling rules will be specified in the SAP. 
12.4.5  Sensitivity analyses for primary endpoint/estimand  
In order to determine the robustness of the logistic regression model used for t he primary 
analysis of clinical failure by [CONTACT_2006] 29, a non -parametric regression model ( Koch et al 1998) will 
also be evaluated using the same explanatory variables as the logistic regression model. 12.4.[ADDRESS_465284] of classifying patients ’ clinical failure status  with missing data , a multiple 
imputation based analysis will be conducted. More details of this approach will be included in 
the study analysis plan.  Other imputation approaches, for exampl e, a worst case analysis, will 
be considered and may be included in the study analysis plan. 
12.4.7  Supportive analyses  
The primary analysis of the clinical failure will be repeated for each of the events in the 
composite endpoint: occurrence of death, mechanical  ventilation, and ICU  care. Separate 
logistic regression models will be fitted to compare the odds between treatment groups for each of the endpoints. The analysis will be performed for both Days 15 and 29. 
As there is uncertainty around the covariates to be included in the primary analysis model for 
the clinical failure by [CONTACT_2006] 29, analyses will be performed considering additional covariates, for example, co -morbidities. These analyses will be defined further in the study analysis plan. 
12.5 Analysis of secondar y endpoints/estimands 
12.5.1  Efficacy and/or Pharmacodynamic endpoint(s)  
Full details of all planned analyses will be included in the study analysis plan. However, a brief description of the approaches used for each endpoint are given below. 
[COMPANY_001]  / Incyte  Confidential  Page 59 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 [IP_ADDRESS]  9-category ordinal sc ale 
The odds of observing a better category (lower number) of clinical status  (9-category ordinal 
scale, WHO 18 -Feb-2020) at Day 15 will be analyzed with a proportional odds model (POM). 
The odds ratio for treatment group (ruxolitinib + SoC therapy  vs. placebo +  SoC therapy) 
estimated from the POM can be interpreted as a summary of the odds ratios obtained from 
separate binary logistic regressions using all possible cutoff points of the ordinal outcome (e.g. the cutof f of level 5 ‘ Non-invasive ventilation or high- flow oxygen’ will combine levels 0, 1, 
2, 3, and 4 versus combined levels 5, 6, 7  and 8). The assumption of POM is that the effect of 
treatment is identical across all possible cutoff points of the ordinal outcome. The proportional odds assumption will be checked by a score test. The model  will include treatment group, 
country, age, gender, and baseline clinical status as covariates. The estimated odds ratios, p -
values and 95% confidence intervals will be prese nted. The analysis will be repeated for the 
data at Day 29.  
The treatment groups will also be compared in terms of at least a one-point improvement, at 
least a two -point improvement , and at least a one -point deterioration in clinical status at Days 
15 and 29 using respective logistic regression model s with the same covariates as for the POM.  
Time to improvement from baseline  category to one less severe category of the ordinal scale 
will be analyzed using a competing risk analysis framework (death will be tr eated as a 
competing risk) . Baseline clinical status will also be included in the model.  
Mean change from baseline in the clinical status  on the 9- point ordinal  scale to Days 15 and 29 
will be summarized by [CONTACT_2939]. This endpoint will also be analyze d using an analysis of 
covariance (ANCOVA) model with factors for treatment group and country, as well as the baseline clinical status as a continuous linear covariate.  
[IP_ADDRESS]  Oxygen saturation  
The proportion of patients with no oxygen therapy (defined as oxygen saturation ≥ 94% on room air) at Days 15 and 29 will be analyzed separately using a logistic regression model with the same covariates as for the primary analyses , with baseline oxygen therapy status included. 
[IP_ADDRESS]  In-hospi[INVESTIGATOR_371915] a competing risk analysis framework (death will be treated as a competing risk) . More details will be provided in the statistical analysis plan.  
The analyses of mortality rates at Day 15 and at Day  29, and proportion of patients requiring 
mechanical ventilation by [CONTACT_2006] 29 are described in Section 12.4.7. 
[IP_ADDRESS]  National Early Warning Score (NEWS2)  
Time to discharge or to a National Early Warning Score (NEWS2) of ≤2 and maintained for 24 
hours (whichever comes first) will be analyzed using a competing risk analysis framework 
(death will be a competing risk)  (Royal College of Physicians 2017) . The model will also 
include treatment group, age, and gender (in the case of the analysis of NEWS2, the baseline 
NEWS2 score will also be included). 
[COMPANY_001]  / Incyte  Confidential  Page 62 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 13 Ethical considerations and administrative procedures  
13.1 Regulatory and ethical compliance 
This clinical study was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical principles laid down in the Declaration of Helsinki. 
(Applicable to US only)  This study is being conducted to determine whether ruxolitinib can 
safely and effectively be used to mitigate, t reat, or cure COVID -19 or limit the harm of the 
COVID- 19 pandemic in accordance with the Secretary of the Department of Health and Human 
Services’ (HHS’s) Declaration under the Public Readiness and Emergency Preparedness Act 
for medical countermeasures against COVID -19 (COVID -19 Declaration) effective February 
4, 2020. The purpose of this study is to test the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm.  This study is authorized to proceed under an approved 
investig ational new drug application (IND) in accordance with the public health and medical 
response of FDA, an Authority Having Jurisdiction as described under the PREP Act, to prescribe, administer, deliver, distribute or dispense this Covered Countermeasure as defined by [CONTACT_371940]’s COVID-19 Declaration. 
13.2 Responsibilities of the investigator and IRB/IEC 
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_30757]/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates, participant recruitment procedures (e.g., advertisements) and any other written information to be provided to participants. Prior to study start, the investiga tor is required to sign a protocol signature [CONTACT_5389]/her agreement 
to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Quality Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site is requested by a regulatory authority, the investigator must i nform [COMPANY_001] immediately that this 
request has been made.  
13.[ADDRESS_465285]. In addition, after study completi on (defined as last patient last visit)  
and finalization of the study report the results of this trial will be submitted for publication and posted in a publicly accessible database of clinical trial results, such as the [COMPANY_001] clinical trial 
results web site and all required Health Authority websites (e.g. Clinicaltrials.gov, EudraCT 
etc.). 
For details on the [COMPANY_001] publication policy including authorship criteria, please refer to the [COMPANY_001] publication policy training materials that were provided to you at the trial investigator 
meetings.  
[COMPANY_001]  / Incyte  Confidential  Page 63 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 13.[ADDRESS_465286] Quality Management System (QMS) that includes all activities 
involved in quality assurance and quality control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.  
Audits of investigator sites, vendors, and [COMPANY_001]  systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a knowledge/risk based approach. 
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001]  processes.  
[ADDRESS_465287] be approved by [CONTACT_5343] , health authorities where required, and the IRB/IEC prior to 
implementation.  
Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety of any participant  included in this 
study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations. 
[COMPANY_001]  / Incyte  Confidential  Page 64 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 [ADDRESS_465288] 
Ahmed, A., Merrill, S.A., Alsawah, F., Bockenstedt, P., Campagnaro, E., Devata, S., Gitlin, 
S.D., Kaminski, M., Cusick, A., Phillips, T. and Sood, S., (2019). Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single- centre, pi[INVESTIGATOR_4251]. 
The Lancet Haematology, 6(12), pp.e630-e637. 
Cai, J., Xu, J., Lin, D., Xu, L., Qu, Z., Zhang, Y., Zhang, H., Jia, R., Wang, X., Ge, Y. and 
Xia, A., (2020). A Case Series of children with 2019 novel coronavirus infection: clinical and 
epi[INVESTIGATOR_908].  Clinical Infectious Diseases.  
Calbet, M, Ramis, I, Calama, E, et al. (2019) Novel inhaled pan-JAK inhibitor, LAS194046, reduces allergen -induced airway inflammation, late asthmatic response, and PSTAT 
activation in brown Norway rats. Journal of Pharmacology and Experimental Therapeutics; 370 (2):137-147. 
Cao, B, Wang, Y, Wen, W., et al A Trial of Lopi[INVESTIGATOR_054]–Ritonavir in Adults Hospi[INVESTIGATOR_371916] -19 (2020) New England Journal of Medicine DOI: 10.1056/NEJMoa2001282 
Published 18- Mar-2020 and updated 20- Mar-2020. 
China CDC Weekly.  (2020) Vital surveillances: the epi[INVESTIGATOR_371917] 2019 novel coronavirus diseases (COVID-19) – China.;2(8):113-22. 
Coon, TA, McKelvey, AC, Lear, T, et al. (2015) The proinflammatory role of HECTD2 in 
innate immunity and experimental lung injury. Science Translational Medicine; 7 (295):295ra109. 
Goldsmith, S.R., Rehman, S.S.U., Shirai, C.L., Vij, K. and DiPersio, J.F., (2019). Resolution 
of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor 
ruxolitinib. Blood Advances, 3(23), p.4131. 
Hermans, M.A., Schrijver, B., van Holten‐ Neelen, C.C., Gerth van Wijk, R., van Hagen, 
P.M., van Daele, P.L. and Dik, W.A., (2018) . The JAK1/JAK2 ‐inhibitor ruxolitinib inhibits 
mast cell degranulation and cytokine release.  Clinical & Experimental Allergy , 48(11), 
pp.1412-1420. 
Hoffmann, J., Machado, D., Terrier, O., Pouzol, S., Messaoudi, M., Basualdo, W., Espínola, 
E.E., Guillen, R.M., Rosa-Calatrava, M., Pi[INVESTIGATOR_288119], V. and Bénet, T., (2016) . Viral and bacterial 
co-infection in severe pneumonia triggers innate immune responses and specifically enhances 
IP-10: a translational study. Scientific reports , 6, p.[ZIP_CODE]. 
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X. and 
Cheng, Z., (2020). Clinical features of patients infected with 2019 novel coronavirus in 
Wuhan, China. The Lancet , 395([ZIP_CODE]), pp.497-506. 
Jagasia, M., Perales, M.A., Schroeder, M.A., Ali, H., Shah, N.N., Chen, Y.B., Fazal, S., 
Dawkins, F.W., Arbushites, M.C., Tian, C. and Connelly-Smith, L., (2020). Ruxolitinib for 
the treatment of steroid -refractory  acute GVHD (REACH1):  a multicenter, open -label, phase 
2 trial.  Blood Journal, pp.blood-[PHONE_7702]. 
[COMPANY_001]  / Incyte  Confidential  Page 65 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 Jakafi® [package insert]. Wilmington, DE. Incyte; (2011). 
Kenderian, S.S., Ruella, M., Shestova, O., Kim, M., Klichinsky, M., Chen, F., Kengle, N., 
Lacey, S., Melenhorst, J., June, C.H. and Gill, S.I., (2017). Ruxolitinib prevents cytokine 
release syndrome after car T -cell therapy without impairing the anti- tumor effect in a 
xenograft model. Biology of Blood and Marrow Transplantation, 23(3), pp.S19-S20. 
Koch, G.G., Tangen, C.M., Jung, J.W. and Amara I.A., (1998). Issues for covariance analysis 
of dichotomous and ordered categorical data from randomized clinical trials and non-
parametric strategies for addressing them. Statistics in Medicine, 17(15-16), pp.1863-1892. 
Maschalidi, S., Sepulveda, F., Garrigue, A. et al. (2016) Therapeutic effect of JAK1/2 
blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood 128:60-71. 
Mehta, P., McAuley, D., Brown, M., et al. (2020) COVID-19: consider cytokine storm 
syndromes and immunosuppression. Lancet 395: 1033-34. 
Royal College of Physicians (2017) National Early Warning Score (NEWS) 2: Standardising 
the assessment of  acute-illness severity in the NHS. Updated report of a working party. 
London: RCP. 
Wang, W., He, J. and Wu, S., (2020). The definition and risks of Cytokine Release Syndrome-
Like in 11 COVID-19- Infected Pneumonia critically ill patients: Disease Characteristics and 
Retrospective Analysis. Medrxiv. 
Wei, M., Yuan, J., Liu, Y., Fu, T., Yu, X. and Zhang, Z.J., (2020). Novel coronavirus 
infection in hospi[INVESTIGATOR_371918] 1 year of age in China. J AMA. 
WHO (18 -Feb 2020). WHO R&D Blueprint. Novel coronavirus. COVID- 19 Therapeutic 
Trial Synopsis (Dated 18- Feb-2020). 
World Health Organization, (2020). Clinical management of severe acute respi[INVESTIGATOR_371919] (2019-nCoV) infection is suspected: interim guidance, 28 January 
2020 (No. WHO / nCoV / Clinical / 2020.3). World Health Organization.  
Xia, W., Shao, J., Guo, Y., Peng, X., Li, Z. and Hu, D., (2020) . Clinical and CT features in 
pediatric patients with COVID ‐19 infection: Different points from adults. Pediatric 
Pulmonology. 
Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T. and 
Wang, Y., (2020) . Clinical course and outcomes of critically ill patients with SARS -CoV-2 
pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet 
Respi[INVESTIGATOR_33593]. 
[COMPANY_001]  / Incyte  Confidential  Page 66 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 Zhao, J., Yu, H., Liu, Y., Gibson, S.A., Yan, Z., Xu, X., Gaggar, A., Li, P.K., Li, C., Wei, S. 
and Benveniste, E.N., (2016). Translational Research in Acute Lung Injury and Pulmonary 
Fibrosis: Protective effect of suppressing STAT3 activity in LPS-induced acute lung 
injury. American Journal of Physiology-Lung Cellular and Molecular Physiology, 311(5), 
p.L868. 
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X. and 
Guan, L., (2020). Clinical course and risk factors for mortality of adult inpatients with 
COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet . 
Zumla, A., Hui, D.S., Azhar, E.I., Memish, Z.A. and Maeurer, M., (2020). Reducing mortality 
from 2019-nCoV: host-directed therapi[INVESTIGATOR_144877]. The Lancet , 395([ZIP_CODE]), 
pp.e35-e36.  
[COMPANY_001]  / Incyte  Confidential  Page 67 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 16 Appendices  
16.1 Appendix 1: Liver event and laboratory trigger definitions & 
follow-up requirements  
Table 16 -1 Liver event and laboratory trigger de finitions  
  Definition/ threshold  
Liver laboratory triggers  
If ALT, AST and total bilirubin normal at baseline:  • ALT or AST > 5 × ULN  
• ALP > 2 × ULN (in the absence of known bone 
pathology)  
• Total bilirubin > 3 × ULN (in the absence of known 
Gilbert syndrome)  
• ALT or AST > 3 × ULN and INR > 1.5  
• Potential Hy’s  Law cases (defined as ALT or 
AST > 3 × ULN and Total bilirubin > 2 × ULN [mainly 
conjugated fraction] without notable increase in ALP 
to > 2 × ULN)  
• Any clinical event of jaundice (or equivalent term)  
• ALT or AST > 3 × ULN accompanied by (general) 
malai se, fatigue, abdominal pain, nausea, or vomiting, 
or rash with eosinophilia  
• Any adverse event potentially indicative of a liver 
toxicity*  
If ALT or AST abnormal at baseline:  • ALT or AST > 2x baseline or > 300 U/L (whichever 
occurs first)  
*These events  cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related 
conditions; non- infectious hepatitis; benign, malignant and unspecified liver neoplasms ULN: upper limit of 
normal  
[COMPANY_001]  / Incyte  Confidential  Page 68 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 Table 16 -2 Follow up requirements for liver laboratory triggers with liver 
symptoms  
  ALT TBL Liver Symptoms  Action  
ALT increase without bilirubin increase:    
  If normal at 
baseline:  
ALT > [ADDRESS_465289]  Normal  
For patients with 
Gilbert’s syndrome: 
No change in baseline TBL  
None  • No change to 
study treatment  
• Measure ALT, 
AST, ALP, GGT, 
TBIL, INR, albumin, CK, and GLDH  (if 
available at local 
laboratory ) in 48-72 
hours.  
• Follow -up for 
symptoms.  If elevated at 
baseline:  
ALT > 2 x baseline 
or > 300 U/L 
(whichever occurs 
ﬁrst) 
  If normal at baseline:  
ALT > [ADDRESS_465290] for 
more than two 
weeks  Normal  
For patients with Gilbert’s syndrome: 
No change in baseline TBL  None  • Interrupt study 
drug 
• Measure ALT, 
AST, ALP, GGT, 
TBIL, INR, albumin, 
CK, and GLDH  (if 
available at local 
laboratory ) in 48-72 
hours.  
• Follow -up for 
symptoms.  
• Initiate close 
monitoring and 
workup for competing 
etiologies.  
• Study drug can 
be restarted only if another etiology is 
identiﬁed and liver enzymes return to 
baseline.  If elevated at baseline:  
ALT > 3 x baseline 
and > 10x ULN  
  If normal at 
baseline:  
ALT > [ADDRESS_465291]  Normal  
None  
ALT increase with bilirubin increase:  
  If normal at 
baseline:  
ALT > [ADDRESS_465292]  TBL > [ADDRESS_465293]  
For patients with 
Gilbert’s syndrome: Doubling of direct 
bilirubin  None  
If elevated at baseline:  
ALT > 2 x baseline 
 
  If normal at baseline:  
ALT > [ADDRESS_465294]  
Normal or elevated  Severe fatigue, 
nausea, vomiting, 
right upper quadrant pain  If elevated at baseline:  
ALT > 2 x baseline 
 
[COMPANY_001]  / Incyte  Confidential  Page 69 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 Table 16 -3 Follow up requirements for liver laboratory triggers 
Criteria  Actions required  Follow -up monitoring  
Total Biliru bin (isolated)      
>1.5 – 3.[ADDRESS_465295]  • Maintain treatment  
• Repeat LFTs within 48-72 
hours  Monit or LFTs weekly until 
resolution to ≤ Grade 1 or to 
baseline 
> 3 - 10 × ULN (in the absence of 
known Gilbert syndrome)  • Interrupt treatment  
• Repeat LFT within 48-72 hours  
• Hospi[INVESTIGATOR_6547]  
• Establish causality  
• Record the AE and contributing 
factors (e.g. conmeds, med hx, 
lab) in the appropriate eCRF Monit or LFTs weekly until 
resolution to ≤ Grade 1 or to 
baseline (ALT, AST, total bilir ubin, 
Alb, PT/INR, ALP and GGT)  
Test for hemolysis (e.g. 
reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)  
> [ADDRESS_465296]  • Discontinue the study 
treatment immediately  
• Hospi[INVESTIGATOR_6548]  
• Establish causality  
• Record the AE and contributing 
factors(e.g. conmeds, med hx, 
lab)in the appropriate eCRF ALT, AST, tot al bilirubin, Alb, 
PT/INR, ALP and GGT until 
resolutiona (frequency at 
investigator discretion)  
Any AE potentially indicative of a 
liver toxicity*  • Consider study treatment 
interruption or discontinuation  
• Hospi[INVESTIGATOR_157055]  
• Establish causality  
• Record the AE and contributing 
factors(e.g., conmeds, med hx, 
lab)in the appropriate eCRF Investigator discretion  
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related 
conditions; non- infectious hepatitis; benign, malignant and unspecified liver neoplasms ULN: upper limit of 
normal  
a Resolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at 
three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6 
months, (4) liver transplantation, and (5) death.  
Based on investigator’s discretion investigation(s) for contributing factors for the liver event 
can includ e: Serology tests, imaging and pathology assessments, hepatologist’s consultancy; 
obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease. 
[COMPANY_001]  / Incyte  Confidential  Page 70 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 16.2 Appendix 2: Clinical status 9-point scale 
Clinical status (9-point ordinal scale): 
Patient State  Descriptor  Score  
Uninfected  No clinical or virological evidence of infection  0 
Ambulatory  (defined as 
not in hospi[INVESTIGATOR_371901])  No limitation of activities  1 
Limitation of activities  2 
Hospi[INVESTIGATOR_371902], no oxygen therapy (defined as SpO 2 ≥ 94% on 
room air)  3 
Oxygen by [CONTACT_88543]  4 
Hospi[INVESTIGATOR_371903]-invasive ventilation or high -flow oxygen  5 
Intubation and mechanical ventilation  6 
Ventilation + additional organ support – pressors, RRT (renal 
replacement therapy), ECMO (extracorporeal membrane 
oxygenation)  7 
Dead  Death  8 
 
Reference:  WHO (18-Feb-2020). WHO R&D Blueprint. Novel coronavirus. COVID -19 
Therapeutic Trial Synopsis (Dated 18- Feb-2020). 
[COMPANY_001]  / Incyte  Confidential  Page 71 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 16.3 Appendix 3: National Early Warning Score 2 (NEWS2)  
 
SpO 2 = oxygen saturation.  
 
The oxygen saturation should be scored according to either the SpO 2 Scale 1 or 2 presented in 
the table above.  The SpO 2 Scale 2 is for patients with a target oxygen saturation requirement of 
88%- 92% (e.g., in patients with hypercapnic respi[INVESTIGATOR_95243], such as chronic obstructive pulmonary disease [ COPD]).  This should only be used in 
patients confirmed to have hypercapnic respi[INVESTIGATOR_95244] a 
prior or their current hospi[INVESTIGATOR_063]. 
The decision to use the SpO 2 Scale 2 should be made by [CONTACT_95322].  In all other circumstances, the SpO 2 Scale 1 should be used. 
For physiological parameter “Air or Oxygen?”:  Any patients requiring the use of oxygen or 
other forms of ventilation to maintain oxygen saturations and support respi[INVESTIGATOR_371920] a score of 2. 
The consciousness level should be recorded according to the best clinical condition of the 
patient during the assessment. Patients who are assessed as “Alert” (A) should be assigned a 
score of 0. Patients assessed as “New Confusion” (C), “Responsive to Voice” (V), “Responsive 
to Pain” (P), or “Unconscious” should be assigned a score of 3. 
Scores should be assigned for respi[INVESTIGATOR_697], systolic blood pressure, pulse, and temperature 
according to the t able above.  
NEWS2 values will be calculated electronically throughout the study by [CONTACT_371941]. 

[COMPANY_001]  / Incyte  Confidential  Page 72 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 Example Case Calculat ion: 
An 82- year-old lady was admitted, tested positive to COVID -19 and admitted to high 
dependency unit for non- invasive ventilation. Her taken observations and corresponding 
NEWS2 score are as follows:  
 
Physiological Parameter  Observation  Component Score  
Respi[INVESTIGATOR_697] (per min)  26 3 
Oxygen saturation (SpO 2 %) 95% 1 
Supplemental Oxygen  Yes 2 
Systolic blood pressure (mmHg)  95 2 
Pulse Rate (bpm)  109 1 
Conscious level  New confusion  3 
Temperature (oC) 39 1 
 Total NEWS2 Score  13 
 
Reference : 
Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the 
assessment of acute -illness severity in the NHS. Updated report of a working party. London: 
RCP, 2017. 
[COMPANY_001]  / Incyte  Confidential  Page 73 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 16.4 Appendix 4: List of CYP3A4 inhibitors and inducers 
Table  16-4 CYP3A4 inhibitors and inducers  
Dual CYP2C9/CYP3A4 inhibitor:  
Fluconazole: Avoid the concomitant use of ruxolitinib with fluconazole doses ≥ 200 mg daily; 
If clinically necessary to use doses ≥ 200 mg daily consultation with Sponsor is required. Please 
refer to Section 6.2. 
Category  Drug Names  
Strong inhibitorsa of CYP3A  boceprevir, clarithromycin, cobicistat, 
conivaptan, danoprevir/ritonavir, eltegravir/ritonavir, grapefruit juice
1, idelalisib, 
indinavir, itraconazole, ketoconazole, lopi[INVESTIGATOR_054]/ritonavir, LCL161, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, sequinavir/ritonavir, telaprevir, 
telithromycin, voriconazole, indinavir/ritonavir, 
tipranoavir/ritonavir, troleandomycin,  
Moderate inhibitorsb of CYP3A  amprenavir, aprepi[INVESTIGATOR_053], atazanavir, 
atazanavir/ritonavir,, casopi[INVESTIGATOR_053], cimetidine, ciprofl oxacin, crizotinib, cyclosporin, duranavir, 
darunavir/ritonavir, diltiazem, dronedarone, 
erythromycin, faldaprevilr, fluconazole
2, 
fosamprenavir, grapefruit juice1, imatinib, 
lomitapi[INVESTIGATOR_5328], netupi[INVESTIGATOR_053],nilotinib, schisandra 
sphenanthera3, tofisopam, verapamil  
Strong inducersc of CYP3A  avasimibe, carbamazepi[INVESTIGATOR_050], enzalutamide, 
mitotane,phenytoin, rifampin, St. John’s wort3, 
rifabutin, phenobarbital,  
Moderate inducersd of CYP3A  bosentan, efavirenz, etravirine, genistein3, 
lersivirine, lopi[INVESTIGATOR_054], modafinil, nafcillin, ritonavir, 
semagacestat4, talviraline4, thioridazine, 
tipranavir,  
The list of CYP inhibitors and inducers was compi[INVESTIGATOR_371921]’s “Guidance for Industry, Drug 
Interaction Studies;” from the Indiana University School of Medicine’s “Clinically Relevant” Table and from the University of Washington’s Drug Interaction Database. Note that this may not be an 
exhaustive list. For a complete and most updated drug list, please check the website 
https://.crediblemeds.org/healthcareproviders/drug- list. 
[ADDRESS_465297] seems to be due to CYP2C19 inhibition by [CONTACT_64127].  
2 Fluconazole is a dual CYP3A4 and CYP2C9 inhibitor. Fluconazole is a strong CYP2C9 inhibitor 
based on the AUC ratio of omeprazole , which is also metabolized by [CONTACT_097]3A; fluconazole is a 
moderate CYP3A inhibitor.  
[ADDRESS_465298].  
4 Drugs not available in the US Market.  
a. A strong inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a 
sensitive substrate for that CYP by [CONTACT_5388] 5- fold. 
b. A moderate inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of 
a sensitive substrate for that CYP by [CONTACT_21316] 5 -fold but equal to or more than 2 -fold 
[COMPANY_001]  / Incyte  Confidential  Page 74 of 74 
Amended Protocol Version 01 (Clean)   Protocol No. CINC424J12301  
 
 c  A strong inducer  for a specific CYP is defined as an inducer that decreases the AUC of a 
sensitive substrate for that CYP by [CONTACT_5388] 80%.  
d. A moderate inducer for a specific CYP is defined as an inducer that decreases the AUC of a 
substrate for that CYP by 50 -80%.  
 